Immune potential and differentiation of equine induced pluripotent stem cells (eiPSC) by Aguiar, Christie
	  
	  
Université de Montréal 
	  
	  
Immune potential and differentiation of equine induced 
pluripotent stem cells (eiPSC) 
	  
	  
par 
Christie Aguiar 
	  
	  
Département de biomédecine vétérinaire 
Faculté de médecine vétérinaire 
	  
	  
	  
Thèse présentée à la Faculté de médecine vétérinaire 
en vue de l’obtention du grade de  
philosophiae doctor (PhD) 
option biomédecine vétérinaire 
	  
	  
	  
Août, 2014 
© Christie Aguiar, 2014
	  
	  
Université de Montréal 
 
 
 
 
 
Faculté de médecine vétérinaire 
 
 
 
 
Cette thèse intitulée 
 
Immune potential and differentiation of equine induced 
pluripotent stem cells (eiPSC)  
 
 
 
présentée par 
 
Christie Aguiar 
 
 
 
 
 
 
 
 
a été évaluée par un jury composé des personnes suivantes : 
Sheila Laverty, président-rapporteur 
Christine Theoret, directrice de recherche 
Lawrence Smith, codirecteur 
Francis Beaudry, membre du jury 
Thomas Koch, examinateur externe 
  
iii	  
	  
Résumé 
Les cellules souches pluripotentes induites (iPSC) ont la capacité de s'auto 
renouveler et de se différencier en une myriade de types cellulaires, ce qui en fait des outils 
intéressants pour la thérapie cellulaire et la médecine régénérative. Le but de cette thèse 
était de déterminer les caractéristiques des iPSC équines (eiPSC) qui peuvent être 
exploitées pour l'usage potentiel en médecine régénérative vétérinaire. Chez le cheval, une 
plaie cutanée est souvent cicatrisée par seconde intention et est sujette à de nombreuses 
complications lorsque située sur le membre, notamment une épithélialisation lente. Ainsi, 
l'hypothèse globale de cette thèse était que les eiPSC pourraient offrir une solution 
novatrice de couverture pour de telles blessures. Avant d'envisager l’utilisation d'eiPSC à 
des fins cliniques, leur immunogénicité doit être étudiée afin de s'assurer que les cellules 
transplantées seront acceptées et intégrées dans les tissus du receveur.  
Le premier objectif de cette thèse était de définir la réponse immunitaire suscitée 
par les eiPSC. Afin d'étudier l'immunogénicité d'eiPSC, l'expression de molécules du 
complexe majeur d’histocompatibilité (MHC) des lignes choisies a été déterminée, puis les 
cellules ont été utilisées dans un modèle de transplantation intradermique développé pour 
cette étude. Bien que  la transplantation allogénique d'eiPSC non différenciées ait induit 
une réponse cellulaire modérée chez les chevaux d'expérimentation, elle n'a pas provoqué 
de rejet. Cette stratégie a permis la sélection de lignées d'eiPSC faiblement immunogènes 
pour la différenciation ultérieure en des lignées d'importance thérapeutique.  
Les eiPSC représentent une solution intéressante et qui, par l’entremise du 
développement d’une lignée de kératinocytes, pourraient servir à la création d’une greffe 
ayant la capacité de former non seulement l’épithélium manquant mais aussi d'autres 
structures accessoires de l'épiderme. Le deuxième objectif de cette thèse était donc de 
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développer un protocole pour la différentiation des eiPSC en lignée de kératinocytes. Un 
protocole visant cette différenciation fut ainsi développé et ce dernier a démontré une 
grande efficacité à produire le phénotype attendu dans une période de 30 jours. En effet, les 
kératinocytes dérivés d'eiPSC (eiPSC-KC) ont montré des caractéristiques morphologiques 
et fonctionnelles des kératinocytes primaires équins (PEK). En outre, la capacité de 
prolifération d'eiPSC-KC est supérieure tandis que la capacité migratoire, mesurée comme 
l'aptitude à cicatriser les plaies in vitro, est comparable à celle du PEK. 
En conclusion, les eiPSC-KC ont des caractéristiques intéressantes pour le 
développement d'un substitut cutané à base de cellules souches, ayant le potentiel de 
régénérer la peau perdue lors de trauma ou de maladie, chez le cheval. Cependant, parce 
que les eiPSC n'échappent pas totalement à la surveillance immunitaire, malgré une faible 
expression du MHC, des stratégies pour améliorer la prise de greffe eiPSC-KC doivent être 
élaborées. 
  
Mots clés: équin /cheval, cicatrisation, médecine régénérative, cellules souches 
pluripotentes induites, kératinocytes, réponse immunitaire, transplantation, greffe	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Abstract 
 Induced pluripotent stem cells (iPSC) have the capacity to self renew and 
differentiate into a myriad of cell types making them potential candidates for cell therapy 
and regenerative medicine. The goal of this thesis was to determine the characteristics of 
equine iPSC (eiPSC) that can be harnessed for potential use in veterinary regenerative 
medicine. Trauma to a horse’s limb often leads to the development of a chronic non-healing 
wound that lacks a keratinocyte cover, vital to healing. Thus, the overall hypothesis of this 
thesis was that eiPSC might offer a solution for providing wound coverage for such 
problematic wounds. Prior to considering eiPSC for clinical applications, their 
immunogenicity must be studied to ensure that the transplanted cells will be accepted and 
integrate into host tissues.    
 The first objective of this thesis was to determine the immune response to eiPSC. 
To investigate the immunogenicity of eiPSC, the expression of major histocompatibility 
complex (MHC) molecules by the selected lines was determined, then the cells were used 
in an intradermal transplantation model developed for this study. While transplantation of 
allogeneic, undifferentiated eiPSC elicited a moderate cellular response in experimental 
horses, it did not cause acute rejection. This strategy enabled the selection of weakly 
immunogenic eiPSC lines for subsequent differentiation into lineages of therapeutic 
importance.  
 Equine iPSC offer a potential solution to deficient epithelial coverage by providing 
a keratinocyte graft with the ability to differentiate into other accessory structures of the 
epidermis. The second objective of this thesis was to develop a protocol for the 
differentiation of eiPSC into a keratinocyte lineage. The protocol was shown to be highly 
efficient at inducing the anticipated phenotype within 30 days. Indeed, the eiPSC derived 
vi	  
	  
keratinocytes (eiPSC-KC) showed both morphologic and functional characteristics of 
primary equine keratinocytes (PEK). Moreover, the proliferative capacity of eiPSC-KC was 
superior while the migratory capacity, measured as the ability to epithelialize in vitro 
wounds, was comparable to that of PEK, suggesting exciting potential for grafting onto in 
vivo wound models.  
 In conclusion, equine iPSC-derived keratinocytes exhibit features that are promising 
to the development of a stem cell-based skin construct with the potential to fully regenerate 
lost or damaged skin in horses. However, since eiPSC do not fully escape immune 
surveillance despite low MHC expression, strategies to improve engraftment of iPSC 
derivatives must be pursued.  
 
Keywords: equine / horse, wound healing, regenerative medicine, induced pluripotent stem 
cells, keratinocytes, immune response, transplantation, grafting  
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 I. Introduction  
 
 The equine industry in the US and the UK exerts an economic impact of $102 
billion and $10 billion per annum, respectively [1]. In Canada, the equine industry 
contributes more than $19 billion annually to the national economy and supports more than 
154,000 jobs for Canadians [2]. Wounds, injuries and trauma are the most common medical 
condition seen in equids, accounting for 25.7% of all conditions [3]. In equine veterinary 
practice, the anatomic location most frequently wounded is the distal limb, including the 
carpus and tarsus, accounting for more than 60% of all wounds [4]. Wounds on horse limbs 
heal with difficulty compared to those in other areas of the body; characteristic features of 
limb wounds are chronic inflammation, excess matrix accumulation, poor wound 
contraction and delayed epithelialization leading to an absence of wound coverage [5]. 
Impaired healing in horses is a common clinical problem that poses welfare implications 
[6] and bears a significant financial impact on the equine industry; for example, 7% of 
injuries leading to the retirement of racehorses are the result of a wound [7].  
Stem cell-based therapies hold promise in equine regenerative medicine and could 
potentially provide the lacking epithelial cover in non-healing limb wounds. Equine 
induced pluripotent stem cells (eiPSC) may be interesting tools in regenerative medicine, 
given their capacity to differentiate into a myriad of cell types, and warrant further study. 
While autologous keratinocytes can be used to engineer skin substitutes, in man they 
require 3-4 weeks for culture expansion, have low proliferative rates, are fragile [8] and, 
most importantly, do not regenerate secondary accessory structures of the skin required for 
normal function [9]. Equine keratinocyte grafts have not yet been developed, and due to the 
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aforementioned disadvantages relating to the use of primary keratinocytes to manufacture 
skin substitutes, eiPSC-derived keratinocyte (eiPSC-KC) grafts may be a superior choice. 
Deriving and testing patient specific iPSC is time consuming and expensive [10], thus 
allogeneic eiPSC-derived grafts may be a logical alternative and are therefore the focus of 
my studies.
	  
	  
 Literature Review 
 1. Skin anatomy and physiology 
 The skin is the largest organ protecting the body from chemical, infectious and 
mechanical hazards. Depending on age and species, the skin constitutes 12-24% of an 
animal's body weight [11]. It is the primary organ that retains water and electrolytes thereby 
protecting the underlying tissues [12]. The skin is composed of two compartments: the 
epidermis and the dermis (Fig.1). 
 
Fig. 1: Normal histological section of equine forelimb skin showing the various 
compartments and structures within them: 1- stratum corneum; 2- stratum basale; 3- 
sebaceous glands; 4- hair follicle; 5- outer root sheath; 6- sweat gland; 7- erector pili 
muscle bundle; 8- blood vessel. 10X magnification; staining with Haematoxylin and Eosin 
(H&E). 
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Epidermis: In the adult, the outermost epidermal component consists of 4-5 layers 
(depending on the species and anatomic location): stratum basale, stratum spinosum, 
stratum granulosum, (stratum lucidum) and stratum corneum [13]. Additional components, 
referred to as skin appendages include hair follicles, sweat glands, sebaceous glands and 
hooves/nails, complete the organ of skin. During fetal development, the epidermis develops 
from two layers; the outermost is called the periderm while the innermost is the basal layer 
(stratum basale) or germinative layer. The periderm acts as a transient covering for the 
epidermis during much of the remainder of fetal development [14]. The basal keratinocytes 
gives rise to the spinous layer (stratum spinosum), which in turn forms the granular layer 
(stratum granulosum). Cells from this layer differentiate to form the outermost keratinized 
layer of the epidermis known as the cornified layer (stratum corneum) (Fig. 2). 
Keratinocytes in situ: The keratinocytes of the stratum basale are typically columnar and 
are replete with keratin filaments around the nucleus and hemidesmosomes (junctions 
between a basal cell and the basal lamina) and desmosomes (junctions between adjacent 
basal cells) [15]. The stratum spinosum is named for the spine-like appearance of the cell 
borders in histological sections attributed to numerous desmosomes joining adjacent 
keratinocytes [16]. Next, the stratum granulosum is so named because the keratinocytes in 
this layer possess electron-dense keratohyalin granules [17]. Finally, the outermost stratum 
corneum is formed of flattened polyhedron-shaped cells called corneocytes, uniquely 
adapted to providing a protective surface.  
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Fig. 2: Epidermis and its strata in equine forelimb skin (40X, H&E stain). 1- squames; 2- 
stratum corneum; 3- stratum lucidum; 4- stratum spinosum; 5- stratum basale; 6- dermis. 
 
 While 90-95% of the cells populating the epidermis are keratinocytes, this 
compartment also includes melanocytes, Langerhans cells and Merkel cells. Keratinocytes 
are 6-70 times stiffer than other epithelial cells because of their keratin intermediate 
filament network [18]. At least 54 keratin (KRT) genes have been studied in the human 
genome and encode proteins classified as either type I (acidic) or type II (basic). Together, 
these form heterodimers that aggregate to generate the intermediate filaments of the 
cytoskeleton or of the hard cornifications of epidermis [19]. Thus keratins contribute to the 
structural integrity and possess a mechanistic role in the functionality of skin.   
 Keratinocytes of the stratum basale are attached to a basement membrane located 
between the outermost epidermal and underlying dermal compartments. The basement 
membrane supporting the basal cells is composed mainly of collagen type IV, 
proteoglycans and nidogen. The basement membrane serves as a scaffold to which basal 
keratinocytes adhere via α6β4 integrins within the hemidesmosomes [20]. The stratum 
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basale possesses three subpopulations of keratinocytes: Keratinocyte Stem Cells (KSC), 
Transit Amplifying (TA) cells and post-mitotic differentiating cells [21]. The KSC 
constitute the most important cell type in the basal layer of the epidermis, and are the 
mitotic cells giving rise to daughter stem cells and to TA cells. The epidermis’ capacity for 
self-renewal is therefore mediated by KSC of the hair follicles as well as those in the 
stratum basale of the interfollicular epidermis, defined as the region of stratified epidermis 
flanked by hair follicles [22]. The KSC are responsible for tissue homeostasis and 
regeneration of the epidermis following injury. After a few rounds of cell division, TA cells 
permanently exit the cell cycle and undergo stratification or terminal differentiation. 
Further epidermal maturation occurs when (suprabasal) spinous cells differentiate into 
granular cells and finally, cornified cell envelopes are assembled by cross-linking of 
structural proteins and lipids [23].  
 The spinous cells differentiate and undergo a complex series of morphological and 
biochemical changes in keratin expression and adhesive properties, lose their organelles, 
enucleate, become cornified, flatten and eventually are sloughed from the surface of the 
skin. These corneocytes form the lipid-rich superficial cornified layer referred to as 
'squames' responsible for waterproofing the epidermis (Fig. 2) [24]. Desquamation leads to 
a loss of cornified cells superficially while epidermal cells undergo continuous cycling 
from the basal KSC layer. During keratinocytes' transition from the basal epidermal layer to 
the granular layer, the nucleus undergoes programmed transformation from a highly active 
status, associated with execution of the genetic program of epidermal barrier formation, to a 
fully inactive condition and, through a process of DNA degradation, becomes a part of the 
keratinized cells of the cornified epidermal layer [21].  Mammalian keratinocyte 
cornification is a multi-step process initiated by a switch in the expression of particular 
KRT genes, followed by the expression of the keratin-bundling protein filaggrin (FIL) and 
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proteins such as involucrin (IVL) and loricrin (LOR), which, together with keratins, 
become cross-linked by transglutaminases to reinforce the formation of a cornified 
envelope across species [25].  
Dermis: The dermal compartment consists of two regions: the papillary dermis and 
reticular dermis [26]. It is a dense, fibroelastic connective tissue constituting the bulk of the 
skin, the thickness of which varies according to body site. The epidermis is anchored to it 
by projections referred to as rete ridges. A network of collagen and elastic fibers provides 
tensile strength and flexibility to the dermis with some elastin and glycosaminoglycans 
(GAG) [11]. Collagen type I is the major collagen of the dermis (around 62%) while 
collagen type III constitutes approximately 15% of the dermis [27]. The fibroblast is the 
major cell type of the dermis; perivascular mast cells are also found in the connective tissue 
along with tissue macrophages. The connective tissue supports the fibroblasts, nerve 
network, epithelial glands, keratinizing appendages and a microcirculatory vascular and 
lymphatic system.  
 The subcutaneous tissue (just deep to the skin) is known as the hypodermis (or 
superficial fascia) and is not considered part of the skin [27]. It contains loose connective 
and adipose tissue and it anchors the skin to the underlying organs while allowing the skin 
to move relatively freely. It also acts as a shock absorber and insulates the deeper body 
tissues from heat loss. 
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  1.1   The role for keratins 
  The major and universal role of keratin filaments is to act as a resilient yet 
adaptable scaffold that endows epithelial cells (e.g epidermal cells) with the ability to 
sustain mechanical and non-mechanical stresses. Keratin proteins significantly impact 
signaling pathways and metabolic processes and profoundly influence specific aspects of 
cytoarchitecture [28]. While the actin cytoskeleton is critical for lamellipodial motility of 
adult keratinocytes and purse-string closure of embryonic epidermal wounds, the keratin 
cytoskeletal network contributes to essential cell and tissue strength during such strenuous 
epithelial movements [29].  
 The process of keratinocyte differentiation in mature epidermis mimics the initial 
development and maturation of keratinocytes during embryogenesis. Epidermal 
keratinocytes are derived from the single-layered surface ectoderm and develop when the 
underlying mesenchyme releases inductive signals [21]. Like other single-layered epithelia, 
the surface ectoderm in fetuses expresses KRT 8 and KRT18 and when the commitment to 
stratification occurs, KRT 8 and KRT 18 expression is downregulated, concomitant with the 
induction of KRT 5 and KRT 14 expression [30]. KRT 5 and KRT 14 are expressed only in 
stratified epithelia or epithelia that have committed to initiate a stratification program (Fig. 
3) [31]. Basal KRT genes are first detected at E9.5 of mice in a highly regional fashion, and 
surprisingly as early as the single layered ectodermal stage [32]. The transition of the 
keratinocyte from the basal to the suprabasal layers is accompanied by the repression of 
basal keratinocyte transcripts KRT 5, KRT 14, and α4β6 integrin, followed by upregulation 
of transcripts for the cornified envelope precursor proteins such as IVL, LOR, and FIL [30]. 
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Fig. 3: Epidermal differentiation program: Keratinocyte stem cells (KSC) residing in the 
basal layer of the epidermis undergo self-renewal, thereby giving rise to another stem cell, 
or can divide to give rise to transit amplifying (TA) cells, which are rapidly dividing cells 
that provide the skin with new epidermal basal cells. New epidermal basal cells 
subsequently detach from the basement membrane and begin the process of terminal 
differentiation. As cells differentiate, they move up to form the different layers of the 
epidermis. Stem and TA cells can be distinguished from terminally differentiated cells on 
the basis of protein expression (yellow box). Each stage of the differentiation program 
(epidermal layers) can also be distinguished according to the proteins expressed (green 
box). 
 
 In spite of a recent revolution in the discovery of novel genes, the most reliable 
criterion to define the epithelial nature of a cell remains KRT gene expression. The pattern 
of keratin protein synthesis provides a useful tool for studying progression through 
complex programs of epithelial differentiation and cycles of epithelial self-renewal [32]. 
The notions of sequence diversity, pairwise regulation, and differentiation-specific 
expression of KRT genes have largely been conserved throughout evolution, suggesting the 
existence of a functional link between keratin proteins and the diversity of structure and 
function of epithelial tissues [33]. Frameshift mutations in epidermal keratins have been 
associated with ‘classical’ and ‘atypical’ forms of epidermolysis bullosa simplex (EBS), 
epidermolytic hyperkeratosis (EHK) and a related family of diseases [34]. Thus, there now 
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is conclusive evidence supporting the involvement of keratins in six broadly defined 
functions: structural support, cytoarchitecture, stress response, regulation of signaling 
pathways towards apoptosis and protein synthesis, and organelle/vesicle distribution [28].  
            1.2   The keratinocyte in vitro   
 Keratinocytes isolated from skin samples can be maintained as a monolayer in 
culture. These cells have a polyhedral, squamous or cuboidal appearance in vitro, similar to 
that observed histologically in skin sections, with the nucleus containing one or more large 
nucleoli [35]. The histological characteristics of the various layers of the epidermis are not 
observed in standard culture conditions but can be induced in 3D culture systems. In 
monolayers, normal tissue architecture is usually absent and cells organize in flattened, 
loosely associated layers, synthesize a different pattern of keratin polypeptides and form 
keratohyalin granules [36]. Studies in man and mouse have shown that cultured epidermal 
cells can differentiate, in response to factors like high calcium concentrations and high cell 
density, from a basal proliferating cell to a flattened squamous, enucleated cell of the 
stratum corneum and are eventually sloughed off into the media [37]. Pioneering studies by 
Rheinwald & Green et al. (1977) have shown that low calcium media promotes 
keratinocyte growth whereas media with calcium concentrations higher than 1.2mM causes 
arrest of cell growth and acceleration of terminal differentiation [38]. Similarly, terminal 
differentiation can be induced either by raising the keratinocytes (in 3D culture systems) to 
the air-liquid interface or by the use of delipidized serum (lacking vitamin A) [39]. 
Keratinocytes grown in low calcium media can be clonally passaged to differentiate and 
stratify similarly to the epidermis in vivo [40]. In vivo, basal keratinocytes are exposed to a 
low calcium concentration while in the supra basal layers keratinocytes differentiate in the 
presence of an increasing calcium concentration gradient.  
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 2.0   Physiology and pathophysiology of wound healing 
 A skin wound occurs when the organ sustains a break compromising its form and 
function [41]. Tissues of the body are capable of healing by two mechanisms: regeneration 
and/or repair. The former occurs in fetuses and in some adult tissues like liver, bone and 
epithelium [4]. Repair is a less efficient process wherein damaged tissue is replaced by 
connective tissue resulting in the formation of a scar. The objective of skin repair is re-
establishment of the protective epithelial cover and recovery of tissue integrity, strength, 
and function. Wound healing occurs by primary or secondary intention. Surgically induced, 
clean and non contaminated wounds that can be opposed with sutures or staples are 
classified as healing by primary intention. Healing by secondary intention occurs in wounds 
with edges that cannot be approximated, wound infection is common and wound healing is 
delayed [42]. This occurs through the four coordinated phases that characterize secondary 
intention healing of full-thickness skin wounds: hemostasis, acute inflammation, cellular 
proliferation and finally, matrix synthesis and remodeling [43]. It relies on the formation of 
granulation tissue that fills in the wound gap and over which epithelialization occurs. The 
process can be associated with substantial scarring. 
 2.1   Wound healing in the horse  
 The equine species can be roughly subdivided into horses and ponies, defined by 
height at the withers of an adult (ponies are <1.48 meters) [5]. The types of wounds 
commonly encountered in horses are lacerations, abrasions, penetrating or puncture 
wounds, contusions etc. Most often, traumatic skin wounds in horses are not amenable to 
primary closure and are forced  to heal by secondary intention because of massive tissue 
loss, excessive skin tension, extreme contamination, or undue time elapsed since injury or 
the cost of treatment [6]. 
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 Wound healing in horses differs from the generic pattern described in humans and 
other commonly studied species such as rodents. In humans and rodents, the inflammatory 
phase lasts two to seven days, the proliferative phase is complete in two to three weeks, and 
the remodeling phase begins at three weeks lasting up to two years [42]. While the three, 
aforementioned phases are conserved, inflammation is sluggish and prolonged in the horse 
extending up to approximately four weeks [44]. Surprisingly, the inflammatory response in 
ponies is stronger and more succinct with a faster initial leukocytic infiltration during the 
first three weeks of healing. Further, leukocytes of ponies produce more reactive oxygen 
species (ROS) and higher levels of other inflammatory mediators like tumor necrosis factor 
(TNF), interleukin -1 (IL-1), chemoattractants, and transforming growth factor beta (TGF-
β). The lower initial production of inflammatory mediators in horses renders debridement 
inefficient, consequently prolonging the inflammatory response and favoring a sustained 
release of cytokines, particularly TGF-β, that may lead to an exaggerated production of 
extracellular matrix (ECM) in the subsequent phases [6]. Indeed, it has been shown that the 
horse activates collagen formation to a greater extent and earlier during wound healing than 
rodents, predisposing it to the development of Exuberant Granulation Tissue (EGT), also 
known clinically as 'proud flesh'.  
 Wound contraction is desirable since it reduces the wound surface area requiring 
coverage by fragile neoepithelium, therefore leading to better cosmesis and function [5]. 
However, in horses, wound contraction is slower than in other species due to the imbalance 
of cytokines and mediators released in the aforementioned phases of healing. Moreover, 
epithelialization is a relatively slow process, further delaying wound repair in comparison 
to other species and to ponies [44]. In cases where fibroplasia is excessive, epithelialization 
is also impaired since keratinocytes are unable to cover the protruding tissue (EGT) that 
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physically impedes migration and inhibits cell mitosis [46]. 
 In addition to species-related physiological differences in the wound healing 
process, horses also show different healing patterns according to the anatomical location of 
the wound. Indeed, while wounds on the head or trunk heal promptly and with few 
complications, those on the distal limb are subject to a number of complications that may 
arise due to anatomical traits such as 1- proximity to the ground that favors wound 
contamination and chronic inflammation; 2- relative deficiency of soft tissue coverage and 
consequently a scant vascular bed and hypoxic conditions [45]; 3- high motion due to the 
presence of numerous joints; and 4- poor wound contraction, related to the absence of a 
panniculus carnosus [6] and to the haphazard orientation of myofibroblasts within the 
granulation tissue [4]. Moreover, wounds on the distal limb must usually heal by secondary 
intention since the skin in this location is under more tension and consequently difficult to 
mobilize around a wound and prone to dehiscence following primary closure.  
 Several studies have compared the healing of experimental wounds created on the 
body and the limb of horses and shown important differences. For example, limb wounds 
double in size (due to wound retraction) after two weeks of creation, only returning to their 
original dimensions after 6 weeks of healing, while body wounds retract to reach a 22% 
increase in size at one week but quickly contract down to their original size one week later 
[46]. Indeed, full-thickness wounds on the body heal 70% by wound contraction and only 
30% by epithelialization while the pattern is reversed in distal limb wounds and leads to the 
formation of a fragile, unesthetic epithelial scar. Moreover, the sluggish and weak 
inflammatory response to wounding leads to the formation of granulation tissue in limb 
wounds that remains irregular and purulent, further delaying epithelialization that 
progresses at a rate of 0.09 mm/day as opposed to 0.2 mm/day in body wounds [47]. These 
differences collectively lead to disparate healing times in wounds of identical size 
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(6.25cm2) created in different locations: 6-8 weeks for body wounds versus 10-12 weeks 
for distal limb wounds [6].  
 Considering healing as a spectrum, the complications that develop in limb wounds 
in horses can lead to chronic nonhealing wounds at one end of the healing spectrum while 
at the other end of the spectrum, fibroproliferative conditions such as EGT ('proud flesh') 
are found to occur [4]. In both cases, the epithelial cover is lacking. 
  3.0   Advanced wound management (selected approaches) 
 Considering the cellular and molecular bases of wound healing, commercial 
products incorporating recombinant growth factors are being used therapeutically 
[53]. However these have exerted only a moderate impact on wound healing due to 
redundancy of the components of the wound repair process (e.g TGF-β [48] and PDGF 
[49]) or because of rapid degradation of these growth factors at the wound site particularly 
in chronic wounds where proteinases abound. It was thus proposed that administration of 
cells and/or tissues that retain the ability to elaborate the full complexity of biological 
signalling may hold the key to accelerate wound healing processes [50]. This has been 
accomplished via the grafting of natural or bioengineered skin or the cells composing it.  
 3.1   Skin grafting 
 Skin grafting is a technique used for coverage of large full thickness skin wounds to 
enhance healing and improve cosmetic and functional outcomes [51]. Wounds at or below 
the carpus and hock in horses are often best treated with a skin graft because wounds in 
these regions are incapable of significant contraction, leaving large areas to be covered by 
weak neoepithelium and, if not grafted, may develop EGT [9]. The two basic types of skin 
grafts are pedicle grafts and free grafts. The former, also referred to as 'axial pattern distant 
flaps' are not used in horses because relatively few axial pattern flaps have been identified 
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in horses compared with humans, dogs and cats [52]. A free skin graft, on the other hand, is 
detached from the donor site and relocated to a distant recipient site where it must create a 
new vascular connection to the wound bed in order to survive. A free skin graft is defined 
by the relation of the donor to the recipient. Autografts are taken from one site on a patient 
and transplanted to another site on the same patient. Isografts are grafts between identical 
twins or highly inbred strains (rare in horses). Allografts are transplanted from another 
individual of the same species, whereas xenografts are transplanted from another species. 
Autografts are the most common type of skin graft used in equine practice because 
allografts and xenografts are often rejected due to host-mediated immune responses causing 
necrosis and sloughing of the foreign tissue [53]. Acute rejection of skin grafts is 
characterized by moderate to severe perivascular inflammation (predominantly 
neutrophilic) with epidermal and/or adnexal involvement, spongiosis and exocytosis, 
epidermal dyskeratosis, apoptosis, or keratinolysis and necrosis evident at the transplanted 
site [54]. Alloreactivity may occur days and weeks after transplantation and cause acute 
graft rejection. Chronic rejection is characterized by parenchymal fibrosis and intimal 
thickening that occurs months to years after transplantation, resulting in a gradual loss of 
graft function [55]. Infiltration of the graft vessels and tissues by macrophages, followed by 
scarring, are prominent histological features of late graft rejection [56]. 
 The poor cosmetic and functional outcome of skin grafts in horses along with the 
lack of redundant donor skin are some drawbacks of skin grafts that can potentially be 
addressed by using tissue engineered skin substitutes. Ultimately, the goal is to generate a 
skin construct that effects the complete regeneration of functional skin, including all its 
layers and appendages, as well as an operational vascular and nervous network, with scar-
free integration within the surrounding host tissue [9].   
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 3.2   Skin substitutes 
 The goal of regenerative therapies for wounds is to renew tissues such that both the 
structural and functional properties of the wounded tissue are restored to pre-injury levels. 
Skin substitutes should display some essential characteristics which include: ease of 
handling, conformability (to the wound site), provision of a vital barrier with appropriate 
water flux, adherence, appropriate physical and mechanical properties, ability to undergo 
controlled degradation, sterility, absence of toxicity and antigenicity, and minimal 
inflammatory reactivity [57]. Skin substitutes should incorporate into the host with minimal 
scarring and pain while facilitating angiogenesis of the construct. Such matrices should 
model the properties of ECM, with the ability to release a multitude of growth factors, 
cytokines and bioactive peptide fragments in a temporally and spatially specific event-
driven manner. These matrices should consist of naturally occurring substances like 
collagen or be prepared from biodegradable polymers. In addition, the restoration of skin 
anatomy must go beyond rehabilitation of structural architecture to include restitution of 
skin pigmentation, nerves, vascular plexus, and adnexa [58].  
 Conventionally, tissue engineered skin consists of cells grown in vitro and 
subsequently seeded onto a scaffold or some porous material which is then placed in vivo at 
the site of injury. Cells are derived from a variety of lineages, from stem cells to 
differentiated somatic cells. These populations can be classified as progenitor, systemic or 
local. The different cells considered for skin substitutes include keratinocytes, fibroblasts, 
adipocytes, melanocytes, hair follicle-associated cells, and various progenitor cells. A 
common multilayered design consists of a highly cellular keratinocyte layer overlying a 
fibroblast-incorporated matrix to mimic the epidermis and dermis, respectively. The dermal 
matrix can be derived from natural sources (decellularized human or pig skin), created from 
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natural proteins (collagens, fibronectin or chitosan), or engineered from synthetic molecules 
(glycolic acid or polycaprolactone) [59].  
 Progress has been made in developing biomaterial substrates that contain various 
growth factors and that can be activated to release stored contents under controlled 
conditions. Ultimately, successful skin engineering relies on recapitulating the optimal 
cellular, matrix, biochemical and biophysical cues that drive tissue regeneration. At present 
there are no commercial skin substitutes available for use in horses, nevertheless, the recent 
development of a 3D skin culture system consisting of primary equine keratinocytes (PEK) 
seeded on tissue scaffolds made of porous polystyrene holds promise for the eventual 
commercialization of such products for horses [60].    
 3.2.1   Cultured epidermal grafts  
 The large-scale production of epidermal cultures suitable for the covering of skin 
defects such as those caused by burn wounds, was developed by a single suspension of 
disaggregated keratinocytes, seeded onto a feeder layer of irradiated (growth arrested) 
mouse 3T3 fibroblasts [38]. Autografting of these cultured epidermal autografts (CEA) 
onto large burn wounds was achieved by detachment of CEA as an intact sheet using the 
enzyme dispase [61]. Since then, CEA grafts have been the 'gold standard' for wound 
coverage in burn victims. In addition to treatment of burn wounds, CEA sheets have been 
used for the treatment of acute and chronic traumatic wounds in human patients. For this 
purpose, an initial population of clonogenic keratinocytes is amplified by subculturing once 
or twice to generate several hundred cultured epithelial cells within a three week period 
[62]. An increased calcium concentration within the culture media (1.8 mM) subsequently 
supports differentiation and stratification of the cells as confluence is approached, such that 
an intact stratified sheet can be formed. Ultimately, grafted cultured keratinocytes generate 
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a normal epidermis over many years and favor the regeneration of a superficial dermis. 
While CEA benefit from histocompatibility, the availability of normal skin from which to 
harvest the cells represents a significant limiting factor in massively burned patients. Thus, 
cultured epidermal allografts offer an ‘off-the-shelf’ skin replacement therapy for 
immediate application to injured skin in the form of a temporary dressing until CEA 
become available [57]. Besides cost, the disadvantages of cultured epidermal grafts (both 
autologous and allogeneic) is the three week waiting time, fragility, poor cosmetic quality 
of healed zones, variable 'take time', sensitivity to infection [8], spontaneous blistering and 
avulsions beyond three months of grafting attributed to the lack of underlying deep dermis 
[63]. Moreover, when keratinocytes achieve confluence, they transform from a highly 
proliferative state to one of growth arrest and stratification. 
 4.0   Regenerative medicine  
 Regenerative medicine was first defined as 'A new branch of medicine that attempts 
to change the course of chronic disease and in many instances will regenerate tired and 
failing organ systems' [64]. This definition has since evolved to include the fields of 
biology, chemistry, engineering, and medicine, encompassing disciplines such as gene-
therapy, biomaterials and molecular medicines to provide solutions to some of the most 
challenging diseases. With the promise of regenerative medicine, cells, tissues and even 
organs can be grown in the laboratory and implanted back into the patient when the body 
cannot self-repair its tissues. Regenerative medicine relies on various approaches such as: 
1- administration of stem cells, referred to as 'cell therapies'; 2- use of bioactive molecules 
with or without cells, referred to as 'immunomodulation therapies'; 3- strategies for in situ 
tissue regeneration, focusing on proliferation and migration of host stem or progenitor cells 
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into target-specific scaffolds and 4- transplantation of tissues or organs, grown in the 
laboratory, referred to as 'tissue engineering' [65]. 
Because the studies reported in this PhD thesis relate to the first approach, that of 
'cell therapies', the remaining portion of the literature review will focus exclusively on this 
component of regenerative medicine. 
 4.1   Veterinary regenerative medicine 
 A relatively liberal legal and ethical regulation of stem cell research in veterinary 
medicine has facilitated the development, and in some instances, clinical translation of a 
variety of cell-based therapies. Volk and Theoret (2013) nevertheless suggest that despite 
rapid advancement of this field, there is a deficiency of supporting in vitro data as well as 
few evidence-based preclinical animal studies [66]. Thus, controlled and well designed 
studies must be carried out until accurate and reliable data is obtained for translation to the 
clinics [67]. Given the paucity of stem cell translational studies in non-human primates, 
large animal models (that include all companion and farm animals besides rodents) may be 
the next most relevant models [66]. For this reason, derivation of stem cell lines in 
veterinary patients may pave the way for the development of future cell-based therapies, 
disease modeling, drug and toxicity screening, biodiversity preservation, transgenic animal 
generation, etc [10].     
 4.2   Stem Cells  
 A stem cell is defined as an undifferentiated cell that can divide, through mitosis, 
for an indefinite period of time, with the capacity to give rise to other undifferentiated stem 
cells (referred to as 'self-renewal') and to more committed descendants through 
differentiation, including fully functional mature cells. Simply put, stem cells are the self 
renewing progenitors of specialized body tissues [68]. 'Stemness' is a cellular property 
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therefore determined by two main hallmarks: 1- the ability of self-renewal and 2- the 
capability to differentiate into mature cell types. Cell potency is the ability to differentiate 
into other cell types or a measure of the number and range of phenotypes into which stem 
cells can develop [69]. The therapeutic potential of stem cells lies not only in their ability to 
contribute healthy, differentiated cells to a compromised tissue bed, but also in their 
production of beneficial growth promoting factors and chemotactic recruitment of 
additional reparative cells.  
 The following diagram shows the hierarchy of pluripotency from the zygote to the 
completely differentiated cell:  
 
  
 
 
 
Fig. 4: Hierarchy of potency in stem cells from the zygote to the adult [67] 
 A totipotent cell sits atop the lineage hierarchy and can generate any type of cell in 
the body, thereby giving rise to an entire organism. A cell that can differentiate into all cell 
types, including the placental tissue, is known as totipotent. In mammals, only the zygote 
and subsequent blastomeres are totipotent [70]. Pluripotent stem cells can give rise to many 
or almost all cell types, as the prefix 'pluri' means many. Pluripotent cells can be isolated, 
adapted and propagated indefinitely in vitro in an undifferentiated state as embryonic stem 
cells (ESC) or induced pluripotent stem cells (iPSC). Multipotent stem cells have the ability 
Zygote (totipotent) 
 ESC and iPSC (pluripotent) 
MSC (multipotent) 
Lineage Stem Cell (oligopotent) 
Tissue-determined Stem Cell (tri/bipotent) 
Terminal Cell (nullipotent) 
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to differentiate into a closely related family of cells. Examples include mesenchymal stem 
cells (MSC) such as hematopoietic stem cells (HSC) that can become red and white blood 
cells or platelets. Oligopotent stem cells have the ability to differentiate into a few cell 
types; examples include lymphoid or myeloid stem cells. These cells are restricted to the 
lineage into which they differentiate and are also called 'lineage stem cells'. For example, 
epithelial stem cells (EpSC) are considered to be developmentally committed such that they 
can form the differentiated cells of their own particular tissue type but not those of any 
other. Tripotent or bipotent cells are tissue determined stem cells and divide into two to 
three cell types [71]. Examples of these include neural stem cells that can divide into 
oligodendrocytes, astrocytes and neurons [72]. Bipotent stem cells can divide into two 
cells, a differentiated cell and another bipotent stem cell. These cells include conjunctival 
stem cells, hepatic stem cells and mammary epithelial stem cells, among others. 
Unipotent stem cells can produce only cells of their own type but possess the property of 
self-renewal, albeit limited, required of stem cells. An example would be (adult) muscle 
stem cells. All of these examples suggest that steady state cell renewal occurs largely from 
unipotent stem cells whereas tissue regeneration following damage may occur from 
multipotent stem cells. This implies that, when regeneration is required, stem cells are 
activated from their dormant state and divide based on the extent of tissue requirement for 
repair. 	  
 4.2.1   Pluripotent Stem Cells (PSC)  
 Pluripotent stem cells are derived from preimplantation embryonic cells, the inner 
cell mass (ICM) of the blastocyst (i.e ESC), or from primordial germ cells of the gonadal 
ridge (embryonic germ cells, EGC). Derivation of PSC is also possible through 
parthenogenesis (phESC) from unfertilized oocytes, through somatic cell nuclear transfer 
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(SCNT) into oocytes, from fusion of ESC with somatic cells, or from somatic cells through 
induction with pluripotency factors (induced PSC, iPSC) [73; 74].  
Embryonic Stem Cells: The most pluripotent stem cell is the ESC derived from the ICM 
of 4-5 day blastocysts. Common methods to test the pluripotency in an ESC line are: 1- 
ability to form embryoid bodies in vitro and subsequent differentiation of those cells into 
specific cell types representing the three germ layers; 2- formation of teratomas upon 
transplantation into an immunocompromised host; 3- derivation of chimeric offspring in 
vivo with a demonstration that the ESC contributed to tissues derived from the endoderm, 
mesoderm and ectoderm, in addition to the germline; and 4- the most stringent of these, 
tetraploid complementation, where the ESC alone gives rise to the embryo proper [75]. 
Numerous human ESC-based therapies have shown promise in animal models and two of 
them, oligodendrocyte precursors and retinal pigment epithelium (RPE), have recently 
entered human clinical trials [76]. The development of ESC lines in mice has enabled the 
production of individual specific ESC lines in domestic and wild animals by adopting 
protocols used for isolation of murine ESC [75]. 
 Equine ES-like cells have been isolated by Saito et al. (2006) [77], Li et al. (2006) 
[78], Guest et al. (2007) [79] and Desmarais et al. (2011) [80]. Li et al. (2006) were 
successful at culturing, for up to 26 passages, ES-like cells that maintained a normal diploid 
karyotype and expressed common markers for ESC such as AP, SSEA-1, SSEA-4, OCT-4, 
TRA-1-60 and TRA-81. The ES-like cells differentiated into three germ layer cells in the 
absence of mouse embryonic fibroblast (MEF) feeder layers and leukemia inhibitory factor 
(LIF). However, horse ES-like cells failed to produce any signs of teratoma in vivo, a 
classic assay for pluripotency, therefore preventing their qualification as 'ESC'; they are 
thus called 'ES-like lines' [81]. Li et al. (2006), suggest that the inability of equine ES-like 
cells to form teratomas in immunopriviledged sites may be a characteristic of this species, 
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given that teratoma formation was achieved in other farm animals [78]. Because the equine 
cells used in the teratoma trials were of late passage, it has been suggested that culture-
induced changes might have reduced their in vivo pluripotency. Suboptimal culture 
conditions can also inadvertently select and enrich an alternative stem cell line [82]. In 
ungulates, trophectoderm and primitive endoderm can outgrow cultured ICM even after 
careful dissection or immunosurgery, and these cells can still form embryoid-like bodies 
reminiscent of those formed by ESC [83]. Thus, outstanding issues including differences in 
pluripotency characteristics among the existing ESC lines, preimplantation embryo 
development, pluripotency pathways as well as culture conditions plague efforts to 
establish authentic ESC lines from horses.   
Induced Pluripotent Stem Cells: iPSC are somatic cells that have been genetically 
reprogrammed to an ESC-like state by being forced to express genes and factors important 
for maintaining the defining properties of ESC. The pioneering discovery of iPSC occurred 
when reprogramming somatic cells by forcing the exogenous expression of specific 
transcription factors, or 'Yamanaka factors': c-MYC, KLF-4, OCT-4 and SOX-2 (MKOS) 
[84]. The iPSC can undergo long term self-renewal when cultured in vitro with defined 
culture media or with growth factors released by feeder layers [85]. The irrefutable 
requirements or 'hallmarks of pluripotency' recommended by the International Stem Cell 
Banking Initiative (ISCBI) include: 1- pluripotency tests; 2- differentiation tests both in 
vitro and in vivo; 3- karyotype analysis to show that the newly generated lines have 
maintained genetic stability, as it is known that prolonged culture of pluripotent cell lines 
can result in genetic abnormalities, commonly causing aneuploidy; 4- determination of cell 
identity, usually performed by DNA fingerprinting and HLA analysis; 5- gene expression 
profiling via a stem cell array, to detect the expression of a common set of genes expressed 
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in undifferentiated cells and down-regulated upon differentiation; and 6- microbiological 
tests to ensure that the cultures are free of any contaminants [86].  
Several viral and non viral methods have been used for iPSC reprogramming; the 
first reprogramming method to be reported was retroviral transduction with the Yamanaka 
factors, achieving a reprogramming efficiency of 0.01-1% [84]. One of the most efficient 
non-viral gene delivery systems for iPSC generation makes use of the Piggybac (PB) 
transposon that has the ability to be excised from its integration site without changing the 
original DNA sequence. The transfected PB transposon carries a single construct containing 
the coding sequences of MKOS that, upon inducible expression, successfully reprogram the 
somatic cells to iPSC [87; 88]. Other non-genetic systems explored for iPSC induction are 
direct delivery of the reprogramming proteins attached to cell penetrating peptides (CPP) 
that contain a high portion of basic amino acids and enable the proteins to cross the plasma 
membrane [89]. Use of microRNA was demonstrated to improve the efficiency of 
reprogramming by use of short RNA molecules that bind to complementary sequences on 
mRNA and block expression of a gene [90]. Use of synthetic modified mRNA is another 
technique to generate RiPSC (micro RNA derived iPSC) that are non mutagenic and highly 
efficient in comparison to the earlier retroviral methods [91]. 
 Irrespective of the induction technique, iPSC have been assessed therapeutically in 
murine models of spinal cord injury, Parkinson's disease, sickle cell anemia, hemophilia, 
limb ischemia, acute myocardial infarction, peripheral vascular disease, diabetes and liver 
regeneration [92]. Additionally, trials in humans for treatment of macular degeneration 
[93], spinal cord injury [94] and recessive dystrophic epidermolyis bullosa (RDEB) are 
underway [95]. While human iPSC technology has been rapidly advancing, iPSC lines have 
also been successfully developed from numerous domestic and wild animal species (horse 
[87], pig [96], sheep [97], goat [98], dog [99], cattle [100], buffalo [101], rhinoceros and 
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snow leopard [102], thus making them more accessible for studies in veterinary research, 
especially since authentic ESC lines have yet to be established in these veterinary species. 
Moreover, given the aforementioned limitations of ESC, iPSC represent a promising 
alternative. 
 Specific to the horse, blastocysts can be efficiently produced in vivo and flushed out 
for ES-like cell isolation however the derivation of true ESC from equine blastocysts is 
challenging due to high costs and the inefficient protocols for the in vitro production of 
embryos [103]. The generation of equine iPSC (eiPSC) could be a promising alternative to 
equine ES-like cells. The pioneering work by Nagy and Smith who were the first to develop 
iPSC from equine fetal fibroblasts using a tetracycline-inducible transposon-based delivery 
of four factors (MKOS), has paved the way for eiPSC research. Equine iPSC maintain a 
diploid karyotype during in vitro culture over 26 passages while colonies exhibit 
morphology similar to that of human iPSC and express AP, OCT-4, NANOG, SSEA-1, 
SSEA-4, TRA-1-60 and TRA-1-81[87]. Embryoid body and teratoma formation containing 
derivatives of the three germ layers is also observed. Equine iPSC have since been 
successfully derived from adult equine fibroblasts via retroviral transduction with three 
transcription factors (OCT-3/4, KLF-4, SOX-2) [104; 105] and also from equine 
keratinocytes, by the same group [1]. 
Several challenges hinder the clinical translation of iPSC, one of which concerns the 
donor cell age and differentiation status [106]. For example, aging cells harbor higher 
levels of genes that limit the efficiency and fidelity of the reprogramming process [107]. 
Other factors to consider prior to translation are the challenges with the efficiency of 
transduction based on the technique used for reprogramming [108]. Genomic insertion of 
viral transgenes, reactivation of transgenes and subsequent tumor formation in chimeric 
animals make viral derived iPSC highly unreliable for therapeutic purposes [109]. Other 
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viral-based methods use lentiviruses, retroviruses and sendai virus; all run the risk of 
insertional mutagenesis due to genomic integration. Besides transgene integration, these 
viral methods also require repeat transduction to maintain transgene expression and are less 
effective in certain cell types [110] and may also cause cells to sit in an intermediate stage 
of reprogramming [111]. 	  
 4.2.1.1   Teratoma formation by PSC 
 The teratoma assay is key to ascertaining pluripotency [112]. Studies have shown 
that teratocarcinoma-like tumors arising upon transplantation of PSC contain malignant 
cells, differentiated tissues and normal immature precursor cells, confirming the close 
relationship between pluripotency and tumorigenicity [113]. The assay is performed by 
injecting cells into the kidney capsule, muscle, subcutaneous space, peritoneal cavity, testis, 
liver or the epididymal fat pad of severe combined immunodeficiency (SCID) mice [114]. 
Teratoma formation is strongly dependent on the site of transplantation/engraftment, 
differentiation status of the cells as well as purity and concentration of the cell population, 
among other factors [115]. Disparate growth patterns of teratomas have also been attributed 
to the environmental cues that influence stem cell behavior [116].  
 Some sites are considered 'immune privileged' because they prevent the occurrence 
of inflammation within an immune mediated environment. These sites are of importance in 
tissue allografting because they affect the survival rate of a transplanted graft [117]. For 
example, teratomas developed in immune privileged sites of the brain, testes and liver 
rapidly produced large tumors containing predominantly immature cells whereas 
subcutaneous implants were significantly slower growing and eventually formed tumors 
composed of differentiated tissues [116]. 
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 4.2.1.2.   iPSC derivatives  
 In a clinical setting, iPSC would first be converted into specific types of 
differentiated cells before transplantation [118]. Directed differentiation of PSC into 
specific cell types is controlled by application of extrinsic signals in a precise temporal 
sequence that mimics development [119]. Recently, iPSC have been differentiated into 
several cell types for patient-specific therapy: neural lineages for generation of midbrain 
dopamine (mDA) neurons intended to treat Parkinson's disease [120], hepatocyte-like cells 
for treatment of liver disease [121], insulin producing cells for treatment of diabetes [122], 
germ cells and oocyte-like cells [123] for treatment of infertility, and keratinocytes for 
grafting onto burn victims and for treatment of epidermolysis bullosa (EB) [124] are some 
examples. All of these studies documented long-term in vivo survival as well as functional 
improvement in at least one relevant animal model of disease. Moreover, iPSC-derived 
retinal epithelium has been approved for clinical trials in human macular degeneration, 
implying that iPSC-derived grafts are not far from the clinic [125]. 
 A major breakthrough of iPSC in dermatology was achieved through the generation 
of keratinocytes capable of populating 3D skin equivalents from normal and RDEB-
diseased humans [126]. In EB and family of diseases, adult KSC are exhausted because of 
the continuous need to repair blister wounds [127]. Results showed that iPSC can be 
differentiated into KSC and skin-like structures, with the potential of treating EB.  In mice, 
iPSC-derived p63/K14+ cells could form a stratified epidermis as well as hair follicles and 
sebaceous glands when grafted into the skin as a cell suspension mixed with normal skin 
fibroblast and dermal papilla cells [128]. Another recent study differentiated human iPSC 
to epithelial precursor cells (EPC) [129]; upon transplantation of human iPSC-EPC with 
trichogenic mouse dermal papilla cells into immunodeficient mice, hair follicle 
reconstitution, due to enhanced epithelial-mesenchymal interactions, resulted. Nissan et al. 
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(2011) worked on the differentiation of human iPSC to melanocytes, which were shown to 
integrate appropriately into organotypic epidermis reconstructed in vitro, as a potential 
treatment of hypopigmentation disorders [130]. Another study developed human 
ESC/iPSC-derived keratinocytes that could generate human epidermal equivalents in an 
air/liquid interface culture exposed to a sequential high-to-low humidity environment [131]. 
Although, the complexity of bona fide skin was not entirely reproduced, the essential 
components for a pigmented 3D skin equivalent have recently become available from the 
aforementioned iPSC studies. 
 Only a few reports of iPSC derivatives differentiated from domestic animals have 
been published. Pig iPSC (piPSC) were differentiated in vitro into rod photoreceptors 
[132], endothelial cells [133], neural cells [134] and hepatocyte-like cells [121]. A single 
report using eiPSC demonstrated neural differentiation cells with features of cholinergic 
motor neurons, including the ability to generate action potentials in vitro, were generated 
from eiPSC in hopes of one day using them to treat equine grass sickness and/or equine 
motor neuron diseases [1].  
 4.2.1.2.1   Immunogenicity of iPSC derivatives 
 Allogeneic cells and tissues face the challenge of the immune barrier, while 
autologous PSC are anticipated to engraft into recipients without the requirement for 
immune suppression [135]. However, deriving and characterizing patient-specific 
(autologous) iPSC is a time-consuming and expensive process (current estimates are 6 
months and tens of thousands of pounds) [10]. A general assumption is that autologous 
PSC will be immune-privileged but this point has been contradicted by Zhao et al. (2011) 
[136]. Their study demonstrated immune rejection of syngeneic iPSC-derived teratomas in 
mice (derived by retroviral and episomal reprogramming) with T-cell infiltration. There 
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was overexpression of tumor-related genes, including Hormad and Zg16, in teratomas 
derived from syngeneic iPSC. This study is however critiqued since retroviruses have been 
shown to cause vector-driven genotoxicity and immunogenicity and because it made use of 
undifferentiated iPSC, consequently limiting clinical interpretation[137]. The 
immunogenicity of iPSC, whether autologous or allogeneic, has been attributed to retention 
of developmental antigens, acquisition of xenogeneic epitopes, and/or expression of 
aberrant antigens over the course of long-term culture to generate iPSC and differentiated 
cells [138]. 
 Two recent reports have contradicted Zhao's findings by showing no 
immunogenicity of in vitro differentiated syngeneic iPSC derivatives. Araki et al. (2013) 
studied the immunogenicity of terminally differentiated skin and bone marrow tissues 
derived from integration-free plasmid borne iPSC and ESC lines. They found no 
differences in the rate of success of transplantation when skin and bone marrow cells 
derived from iPSC were compared with ESC-derived tissues; moreover, both skin grafts 
and bone marrow were very rarely rejected in the syngeneic setting [118]. Specifically, 
there was limited or no immune response such as T-cell infiltration, for tissues derived 
from either iPSC or ESC, and no increase in the expression of the immunogenicity-causing 
Zg16 and Hormad1 genes in regressing skin and teratoma tissues. Skin samples from the 
tails of the chimeric mice were prepared and then transplanted onto the backs of syngeneic 
GFP- allogeneic mice. All of the iPSC differentiated and GFP+ transplanted grafts could be 
sustained over a 10-month period.  
 A similar study showed that lentivirally reprogrammed murine iPSC, episomal iPSC 
(EiPSC) and ESC, when terminally differentiated in vitro into endothelial cells, hepatocytes 
and neuronal cells then transplanted syngeneically, led to 100% graft survival with no 
evidence of immune rejection as measured by T-cell infiltration [139]. These findings 
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suggest that iPSC-derived endothelial cells, hepatocytes and neuronal cells are potentially 
non immunogeneic and thus immuneprivileged. 
 4.2.2   Adult Stem Cells (ASC) 
  Adult stem cells are undifferentiated cells, found throughout the body after 
development, that multiply by cell division to replenish dying cells and regenerate damaged 
tissues [140]. Adult stem cells are post natal stem cells, also known as somatic stem cells, 
and can be found in juvenile as well as adult mammals. Examples of ASC are EpSC, HSC, 
mammary stem cells, intestinal stem cells, endothelial stem cells, neural stem cells, 
olfactory stem cells, neural crest stem cells, testicular stem cells and MSC [141].  
 4.2.2.1   Mesenchymal Stem Cell (MSC) 
 Mesenchymal stem cells are multipotent stromal cells that can differentiate into a 
variety of cell types, including osteoblasts, chondrocytes, and adipocytes. Due to the 
current controversies in the definition of MSC, the International Society for Cellular 
Therapy (ISCT) has suggested some phenotypical and functional characteristics for 
identification of MSC. These include 1- plastic adherence; 2- expression of the cluster of 
differentiation (CD) markers CD105, CD73 and CD90, and lack of expression of CD45, 
CD34, CD14 or CD11b, CD79a or CD19 and HLA-DR surface molecules; and 3- 
multipotency differentiation capacity [142]. The ISCT suggests that plastic-adherent cells 
generally described as MSC should be retermed 'multipotent mesenchymal stromal cells', 
while the term MSC should be reserved for cells with in vivo demonstrations of long-term 
survival with self-renewal capacity and tissue repopulation with multilineage differentiation 
[143]. An exception to the classification of MSC based on plastic adherence, are non-
adherent HSC that differentiate into myeloid and lymphoid lineages [144]. 
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 Progenitors are proliferative cells with a limited capacity for self-renewal (short 
term) and are often unipotent, whereas stem cells self renew throughout the lifetime of the 
animal (long term) [145]. Perinatal and midtrimester MSC have shown advantageous 
growth and plasticity properties over adult MSC. These fetal MSC were readily expandable 
and senesced later in culture than their adult counterparts attributable to their longer 
telomeres and greater telomerase activity [146]. 
  Based on the source MSC are called bone marrow-derived MSC (BMSC), adipose-
derived MSC (AMSC), umbilical cord blood-derived (UCB)-MSC [67]. These have lately 
been gaining therapeutic relevance for several clinical conditions [66]. The BMSC have the 
advantage of being relatively noninvasively obtained and have a greater capacity to 
differentiate into tissue types of the musculoskeletal system in comparison with other MSC 
[147]. Therefore, despite the wide diversity of tissue sources from which to harvest MSC, 
many investigators employ BMSC for the treatment of musculoskeletal afflictions [148]. 
The drawback of culture-expanded BMSC is the time lag of three to six weeks from bone 
marrow aspiration until readiness for treatment. In addition, BMSC are more difficult to 
isolate with increasing donor age and show reduced plasticity and growth as a factor of 
both increasing donor age and number of in vitro passages [146].   
 In the skin wound context, experimental studies have shown that BMSC enhance 
healing in normal and diabetic mice by significantly accelerating wound closure, via 
increases in cellularity, angiogenesis and the rate of epithelialization [149; 150]. In a rat 
model of burn wounds, injection of BMSC significantly decreased the rate of apoptosis in 
dermal cells in and around the initial wound [151]. In human burn patients, administration 
of BMSC resulted in mild pain relief and decreased plasmarrhea after 30  min, 
neovascularization and epithelialization was improved and skin grafts were accepted better 
than previous cases of allogeneic skin grafting [152; 153].  
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 In conclusion, MSC are currently being used therapeutically in various organ 
systems in humans, based on the promising results obtained in various animal models. 
However MSC have disadvantages such as limited capacity to proliferate, rapid loss of 
differentiation potential, differentiation  into few selected lineages and are thus unlikely to 
regenerate the entire organ of the skin, contrary to what has been achieved by iPSC studies 
[126].  
 4.2.3	  	  	  Immunogenicity of MSC 
 An intriguing characteristic of MSC is their ability to act as immunomodulators and 
pro-angiogenic agents [154]. This is potentially mediated through the secretion of a variety 
of trophic signals that favor engraftment and/or endogenous regeneration [155]. The 
therapeutic use of MSC has been encouraged by low expression of MHC-I and absence of 
expression of MHC-II molecules that endows MSC with the potential to escape recognition 
by alloreactive CD4+ T-cells [154]. Under non-inflammatory conditions, human and mouse 
MSC are MHC-II-, suggesting they are hypoimmunogenic through the control of 
alloantigen expression [156].  
 Equine regenerative medicine has evolved rapidly with the use of MSC for 
musculoskeletal disorders, given their immunomodulatory properties [67]. A study 
comparing MSC from equine bone marrow, adipose tissue and umbilical cord was 
conducted to determine the best source for banking of equine MSC for allogeneic therapy. 
All types of MSC showed low or negative expression of MHC-II (Table I). A preclinical 
safety study in 16 horses investigated autologous and allogeneic placentally-derived MSC 
injected intra-articularly. While MSC were MHC-I+, MHC-II - and CD86-, there were no 
significant differences in the degree and type of inflammation elicited between self and 
non-self-MSC [157]. Nevertheless, while the potential immunomodulatory effect of MSC 
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on various disease states is promising, the lower differentiation potential of MSC in 
comparison to iPSC implies a weaker regenerative capacity. 
 
SOURCE TISSUE STEM CELL IMMUNE RESPONSE 
 
Embryonic 
Blastocyst  
(5-7 days) 
 
ESC 
Low expression MHC-I 
and MHC-II antigens 
[158] 
 
Fetal 
 
Fibroblasts 
 
iPSC 
Low expression MHC-I 
and MHC-II antigens 
[159] 
 
Newborn 
Umbilical cord blood 
Whartons Jelly 
Placenta 
 
UCB-MSC 
 
Absence of MHC- II 
[160] 
 
 
 
Adult 
Bone marrow 
Adipose 
BMSC 
A-MSC 
MHC-I+, absence of 
MHC-II [154] 
Others: Epidermal 
(skin), Neuronal, 
Muscle, etc 
iPSC 
NSC 
Low expression         
MHC-I and MHC-II [161] 
Table I: Stem cell types, sources and immune response they generate 
 4.3	  	  	  Immunological hurdles in stem cell transplantation 
 The major problem in cell and tissue transplantation is that the recipient’s immune 
system may cause rejection of the graft. In the absence of immunosuppression upon 
transplantation, the immune system of the recipient mounts a rejection response towards 
foreign cells and tissues, while transplantation of autologous cells / tissues are recognized 
by the host as its own [162]. Transplant rejection, as mediated by the MHC complex, is of 
one of three types: hyperacute, acute or chronic [54]. Rejection is initiated by recognition of 
MHC alloantigens by the T-cells of the immunocompromised recipient. In humans, the 
MHC is referred to as the human leukocyte antigen (HLA) while in horses it is referred to 
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as the equine leukocyte antigen (ELA). Specifically, HLA/ELA refers to the protein 
molecule whereas the MHC is the region on the genome that encodes for this protein [55].  
 Adequate compatibility of donor and recipient MHC, ensured through prior typing 
and matching, is crucial to enhance graft acceptance [163]. Nevertheless, although MHC 
matching significantly improves the success rate of tissue and cell transplantation, it does 
not, in itself, prevent rejection. This is because MHC typing is imprecise, owing to the 
polymorphism and complexity of the MHC gene [164]. In addition to MHC-I molecules, all 
cell types express mHC antigens that are derived from mitochondrial and H-Y gene 
products. While they are less critical to acceptance of cell transplants than are MHC 
antigens, mHC antigens can nevertheless initiate allograft rejection, particularly when many 
mHC antigens act together [165].  
 In mice, MHC-I molecules were not detected by flow cytometry on ESC nor on 
undifferentiated iPSC [161]. Similarly, in Mauritian cynomolgus macaques (CM), the 
MHC-I expression by undifferentiated iPSC was found to be very low while MHC-II 
expression was undetectable. Deleidi et al. (2011) determined that the MHC genetic 
diversity in CM is distributed among seven haplotypes and that specific haplotypes can be 
identified by genetic screening using a panel of microsatellite markers, permitting MHC-
matched iPSC transplantation [166]. Likewise, ELA haplotyping, using microsatellite PCR, 
has been characterized by Tseng et al. (2010) [167]. However, there is currently no data on 
the immunogenicity of eiPSC despite the recent development of eiPSC by other groups 
[105]. Undifferentiated porcine iPSC were found to express only low levels of MHC-I and 
moderately increased levels of MHC-I on their differentiated derivatives, whereas MHC-II 
was rarely expressed on both undifferentiated and differentiated porcine iPSC [168].  
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 Possible solutions to prevent allorecognition and rejection include the development 
of mild immunosuppressive regimens (e.g. monoclonal antibodies targeting NK cells 
and/or T-cell subsets) sufficient to induce tolerance to allogeneic iPSC-derived cells [169]. 
Other proposed strategies for inducing tolerance in stem cell grafts are based on clinical 
efficacy in treating graft versus host disease (GVHD). Inhibition of signaling pathways 
(tyrosine kinase, JAK, PKC) through pharmacological approaches has been achieved using 
imatinib mesylate, sotrastaurin etc. [170]. Suppression of neovascularization by inhibition 
of VEGF has also been shown to ameliorate symptoms of GVHD [171]. Immunotherapy by 
blockade of lymphocyte molecules like CD2, CD20 [172], co stimulatory molecule 
blockade of CD28, CD40, and inhibition of cytokines like TNF-α, IL-1, IL-10 are other 
suggested strategies to encourage graft acceptance [173]. Induction of tolerance has been 
shown by use of regulatory T-cells, DC, NK and MSC [174]. However, any level of 
immunosuppression would likely increase the risk that rare undifferentiated PSC in an 
iPSC-derived population will form teratomas [158].  
 4.4   Cell and tissue based skin therapy 
 As a result of the aberrant healing pattern of skin wounds in horses, particularly 
those located on the limbs, a large area of scar tissue covered by fragile neoepidermis 
devoid of essential adnexal structures typically develops. Current treatments are only 
partially effective in accelerating healing and ensuring an outcome that is both cosmetic 
and functional. Skin grafts and cultured epidermal grafts are the gold standard for coverage 
of large wounds and burns in humans. Presently, the preparation of CEA requires a sample 
of donor tissue followed by extensive cell expansion lasting about three weeks before 
transplantation is possible [8], while CEAl only suffice as a temporary dressing [63]. 
Moreover, the isolation technique is difficult to standardize and the tissue-derived primary 
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cells are consequently heterogeneous [65]. Furthermore, CEA used for the treatment of 
human burn patients only provide wound coverage by epithelial sheets of keratinocytes 
lacking the capacity to form all the other cell types of the skin, especially the underlying 
dermis that is crucial to cosmesis and stability of grafts [175]. Although KSC are the most 
therapeutically relevant cell type for skin grafting within CEA, other stem cell sources have 
recently been exploited. Adult stem cell (i.e ADSC) have been shown to differentiate in 
vitro into both mesenchymal and non-mesenchymal lineages and a few studies have shown 
that MSC can transdifferentiate into keratinocyte-like cells and develop stratified 
epithelium when seeded on decellularized dermis [176] but are unable to regenerate the 
secondary accessory structures of the skin such as sweat glands and hair follicles.  
 Pluripotent stem cells such as iPSC represent an important stem cell source for 
dermatology because of their ability to differentiate into almost all types of cells in the 
body, providing a renewable source of cells with unlimited proliferative capability [177]. 
Although autologous iPSC would constitute the ideal 'personalized therapy', the logistics of 
achieving this on a large scale are daunting, owing to the relatively low efficiency and, 
consequently, the high cost of inducing pluripotency [158]. Thus, allogeneic iPSC-derived 
skin substitutes would appear to offer a potential 'off-the-shelf' solution. The obvious 
advantages of an allogeneic approach are that the donor can be selected ahead, qualified by 
HLA matching, and tested for absence of different disease organisms, such that the cells are 
prepared in advance so they are immediately available when needed by a patient [178]. 
 Recent evidence suggests that iPSC can be differentiated into adnexal structures as 
well as nervous, vascular, immune and pigment components of the skin [175]. Similarly, 
eiPSC are anticipated to differentiate into multiple cell types, in response to appropriate 
differentiation protocols, ultimately enabling restoration of the equine skin's stratified 
epithelium, pigmentation, nervous and vascular plexuses, as well as adnexa (hair follicles, 
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sweat and sebaceous glands) that together constitute the functional organ of the skin. The 
concept of integrating different populations of iPSC-derivates to create complex tissue 
structures may prove more applicable along with the use of 3D scaffolds [59].  
 Nevertheless, two crucial issues must be resolved before such specifically 
differentiated cells can be exploited in a clinical setting. First, determining the immune 
response of undifferentiated iPSC and their derivatives; second developing standardized 
differentiation protocols to generate iPSC-derived keratinocytes to be used in future 
applications of wound grafting.
	  
	  
II. Rationale  
Horses frequently suffer from chronic non-healing wounds lacking an epithelial 
cover and thus might benefit from skin grafts to provide much-needed coverage. Because of 
a paucity of donor skin in this species, it is interesting to consider tissue-engineered skin 
substitutes such as those available in human medicine. Ideally, the cells used to construct 
these substitutes should ensure regeneration of all the components of normal skin, including 
its specific adnexal structures as well as nervous and vascular plexuses. Pluripotent stem 
cells, such as the iPSC recently engineered in horses, seem promising candidates on 
account of their properties of unlimited self-renewal and potential to differentiate into most 
cell types of the body. Prior to considering eiPSC for therapeutic purposes, their 
immunogenicity must be studied to predict whether eiPSC-derived grafts would be 
accepted following transplantation. It was originally assumed that autologous iPSC grafts 
would circumvent the need for tissue matching prior to transplantation but a recent study 
challenges this assumption [136]. Moreover, significant economic and time constraints are 
associated with the derivation of autologous (patient-specific) iPSC. Allogeneic grafts 
might therefore be more appealing since they theoretically should provide an off-the-shelf 
product. My first study thus investigates the immune potential of allogeneic eiPSC both in 
vitro and in vivo. The subsequent study aims to develop an efficient protocol to drive eiPSC 
to commit to a keratinocyte lineage (eiPSC-KC) in view of generating the cells required to 
engineer a stem-cell based skin construct for horses.  
 
 
	  
	  
 III. Aims and Hypotheses 
The main hypothesis of this thesis was that equine iPSC (eiPSC) have characteristics that 
can be harnessed for potential use in veterinary regenerative medicine.  
SPECIFIC HYPOTHESES  
1. Allogeneic equine iPSC weakly express MHC-I and II molecules and therefore will 
not elicit a rejection response when injected intradermally in horses. 
2. Equine iPSC can be induced to differentiate into cells of the keratinocyte lineage 
(iPSC-KC) with morphological and functional characteristics resembling those of primary 
equine keratinocytes. 
OBJECTIVES 
The long-term objective of this research program is to develop a novel approach to engineer 
a functional skin substitute to be used for the management of wounds or skin disease in 
horses.  
Short-term objectives:  
1. To measure the expression of MHC molecules on allogeneic eiPSC and describe 
their immunogenicity using intradermal testing in horses.  
2. To develop an efficient method to drive the differentiation of eiPSC into a 
keratinocyte lineage (iPSC-KC). 
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DIFFERENTIATION OF EQUINE INDUCED PLURIPOTENT STEM CELLS INTO A 
KERATINOCYTE LINEAGE 
Aguiar C., Therrien J., Lemire P., Segura M., Smith L., Theoret C. 
Summary 
Reasons for performing study: Skin trauma in horses often leads to the development of chronic 
non-healing wounds that lack a keratinocyte cover, vital for healing. Reports in mouse and man 
confirm the possibility of generating functional keratinocytes from induced pluripotent stem cells 
(iPSC),thus presenting a myriad of potential applications for wound management or treatment of 
skin disease. Similarly, differentiation of equine iPSC (eiPSC) into a keratinocyte lineage should 
provide opportunities for the advancement of veterinary regenerative medicine.  
Objectives: The purpose of this study was to develop an efficient method for the differentiation 
of eiPSC into a keratinocyte lineage. It was hypothesised that eiPSC can form differentiated 
keratinocytes (iPSC-KC) comparable to primary equine keratinocytes (PEK) in their 
morphological and functional characteristics. 
Study Design: Experimental in vitro study.  
Methods: Equine iPSC established using a non-viral system, were treated for 30 days with 
retinoic acid and bone morphogenic protein-4 to induce directed differentiation into iPSC-KC. 
Temporospatial gene and protein expression by eiPSC-KC was measured at weekly intervals of 
differentiation and in response to calcium switch. Proliferative and migratory capacities of 
eiPSC-KC were compared to those of PEK. 
Results: Equine iPSC, upon directed differentiation, showed loss of pluripotency genes and 
progressive increase in pancytokeratin expression indicating ectodermal specification into 
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keratinocytes. High differentiation efficiency was achieved, with 82.5% of eiPSC expressing 
keratin 14, a marker of epidermal-specific basal stem cells, after 30 days of directed 
differentiation. Moreover, the proliferative capacity of eiPSC-KC was superior while the 
migratory capacity (measured as the ability to epithelise in vitro wounds) was comparable to that 
of PEK. 
Conclusions: This proof of concept study suggests that eiPSC can successfully be differentiated 
into equine keratinocytes (eiPSC-KC) with features that are promising to the development of a 
stem cell-based skin construct with the potential to regenerate lost or damaged skin. 
Introduction 
A large study by the National Animal Health Monitoring System found that injuries are the 
primary medical condition affecting horses, more common than lameness, colic or respiratory 
disease; moreover, 20% of euthanasias are due to skin wounds [1]. When a wound is located on 
the limb, as is the case 60% of the time [2], it tends to heal with difficulty, often leading to a 
chronic non-healing wound lacking an epithelial cover [3].  
Traditional skin grafting, while considered the “gold standard” for managing wounds, achieves 
limited success in horses due to the scarcity of donor skin [2]. Consequently, there is a need to 
engineer functional skin, including all its layers and appendages, with pigment and operational 
vascular and nervous networks, that will integrate into surrounding host tissue in a scar-free 
manner [3]. At present, no model of artificial replacement skin completely replicates the 
uninjured organ, either in human or veterinary medicine. Importantly, traditional cultured 
epidermal autografts lack the accessory adnexal structures of skin [3]. Hence, scientists have 
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turned to stem cells, capable of multi-lineage differentiation, to populate tissue-engineered 
constructs [4].  
Recent breakthroughs in the generation of induced pluripotent stem cells (iPSC) provide a novel 
renewable source of cells with embryonic stem cell (ESC)-like properties and that circumvent 
ethical issues since they are engineered without destroying an embryo. Moreover, immunological 
rejection is minimised since autologous iPSC can be generated. Reprogramming to a pluripotent 
state was originally achieved by viral transduction using the Yamanaka factors [5]. Induced 
pluripotent stem cells have been generated by transduction with reprogramming factors using 
retroviral [5] or adenoviral methods [6], non viral methods [7], protein transduction [8], small 
molecules [9] etc.  Nagy and Smith recently reported the establishment of equine iPSC (eiPSC) 
using a non-viral, PiggyBac system which was used in the study described herein [10]. While the 
eiPSC used in the current study were derived from fetal donors, protocols are available for 
deriving eiPSC from adult cells thereby enabling the production of autologous lines [11]. In 
parallel, progress has been made in differentiating iPSC into several cell types in view of 
eventual therapeutic use. Following specific protocols, iPSC have been differentiated into 
hepatocytes [12], pancreatic cells [13], cardiomyocytes [14], adipocytes [15] etc. that have 
proven functional in experimental models and are being used for the treatment of various 
diseases [16]. More recently, eiPSC have successfully generated cells with features of 
cholinergic motor neurons [17]. Murine iPSC have also been differentiated into keratinocytes 
capable of reconstituting a stratified epidermis and its appendages when grafted onto mice [18], 
generating much excitement in the field of cell-based therapies for chronic non-healing wounds. 
To fully exploit the promise of eiPSC derivatives in equine medicine, reproducible and efficient 
differentiation protocols are now necessary. Therefore , it was hypothesised that eiPSC can be 
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differentiated into keratinocytes using the procedure developed for murine iPSC [18]. The aim of 
the current study was to develop a protocol to differentiate eiPSC to a keratinocyte lineage for 
eventual grafting onto skin wounds in horses. Here we demonstrate that eiPSC can successfully 
be differentiated into keratin-expressing cells (eiPSC-KC). Their phenotype resembles that of 
primary equine keratinocytes (PEK) that express markers such as KRT 18, KRT 14 and integrins 
when within the basal layer of skin. Upon commitment to stratification the keratinocytes express 
markers of epidermal differentiation such as KRT 1 and KRT 10 and, finally, terminally 
differentiate and express involucrin (IVL) markers [19]. 
Given the pluripotent nature of iPSC, our ‘proof of concept’ study represents an important 
advance for equine regenerative medicine since, in principle, eiPSC would provide an 
inexhaustible source of cells that might be used to engineer a fully functional skin substitute for 
wound management or skin disease in horses.  
Materials and Methods 
Cell cultures 
Horse skin was obtained during castration surgery at the Centre hospitalier universitaire 
vétérinaire of the Université de Montréal. Primary equine keratinocytes (PEK) were isolated and 
cultured as previously described [20] except using a 2% seruma formulation for maintenance. 
The equine iPSC line used in these experiments (line H2A) was obtained by transfection of 
fibroblasts obtained from a day-40 fetus using a PiggyBac transposon system containing the 
tetracycline inducible Yamanaka factors and constitutively controlled Green Fluorescent Protein 
(GFP), then propagated in culture as described [10]. Equine iPSC media consists of DMEM high 
glucosea, 2 mM GlutaMaxa, 0.1 mM non-essential amino acidsa, 0.1 mM betamercaptoethanolb, 1 
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mM sodium pyruvatea, 50 U/ml penicillin/streptomycina and 15% fetal bovine seruma, 1000U/ml 
leukaemia inhibitory factor (LIF)c, 10 ng/ml bFGFd, 1.5 µg/ml doxycyclineb, 3 µM GSK 
inhibitore, 0.5M MEK inhibitore, 2.5 µM TGF inhibitore, 5µM thiazovivine, and 25 µM ALK 
receptor inhibitore.  
Keratinocyte differentiation media consists of DMEM/F12a, 2% FBSa, HEPES buffera, 25µg/ml 
gentamicina, 100X penicillin-streptomycina, 0.5 µg/ml amphotericin Ba, 10 ng/ml recombinant 
mouse EGFa, 5 µg/ml recombinant human insulina and 30 µg/ml bovine pituitary extracta. 
Directed differentiation of eiPSC into a keratinocyte lineage  
Upon characteristic colony formation, eiPSC (Fig. 1A) expressing key pluripotency markers 
OCT-4, SOX-2, KLF-4 and NANOG were separated from mouse feeder layers (MEF) cultured in 
mediaa free of LIFc and doxycyclineb to permit differentiation and loss of pluripotency marker 
expression (Fig. 1B). The cells were cultured for two weeks to enable the formation of embryoid 
bodies (EB) (Fig. 1C). The EB were treated with 1 µM retinoic acid (RA)b for three days 
followed by 25 ng/ml of bone morphogenic protein 4 (BMP-4)b for three days, as previously 
described [18]. Upon EB formation, the media was changed to a differentiation media that 
permits selection of ectodermal differentiated cells by their attachment to collagena coated platesf 
[21]. The attached cells were cultured in keratinocyte differentiation media and analysed for gene 
and protein expression at 0, 7, 14 and 30 days of differentiation. The latter time was when the 
morphology of differentiated eiPSC matched that of PEK (Fig. 1D; Fig. 1E). Once 
differentiation was complete, eiPSC-KC and PEK were treated with 1.8mM CaClb-supplemented 
keratinocyte media to induce stratification [22] and studied at 0, 24, 48 and 72 hours. 
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Immunocytochemistry 
Cells were fixed in 4% paraformaldehydeb and blocked with 5% goat seruma for 1h. Incubation 
with mouse anti-pancytokeratin (PANCK) antibody (MA1-82041g, 1:100) was carried out 
overnight at 4°C. Goat anti-mouse Cy3 (115-001-003h, 1:400) was then added for 1h at room 
temperature and nuclei were counterstained with 10 mg/ml DAPIb. Primary and secondary 
antibodies were verified for species specificity and cross reactivity using Western blot (data not 
shown). Negative control of equine fibroblasts were used for primary and secondary antibodies 
(Supplemental figure 2).  Immunostaining was visualised by fluorescence microscopy (Axio 
Observer Z1)i. Digital images were acquired using the image-analysis software Zeni and 
immunoreactivity was quantified using a plugin of Image J, NIH softwarej in a minimum of five 
random high power fields, as previously described [23]. Data are representative of three 
independent differentiation experiments performed using the same cell line approximately two 
months apart. 
Reverse transcription and quantitative real-time PCR (qRT-PCR) 
Equine iPSC samples were collected in triplicate following 7, 15 and 30 days of directed 
differentiation, to confirm loss of pluripotency genes and to measure changes in the expression 
of keratin (KRT) 10, 14, 18 and involucrin (IVL) genes in response to ectodermal morphogens 
(RA and BMP-4). Fibroblasts were used as a negative control for keratin expression while 
primary keratinocytes were used as positive controls.  
Total RNA was extracted using the RNeasy mini kitk, then reverse transcribed to mRNA and 
cDNA using the PCR T3000 Thermal cyclerl. Reverse transcription was performed using 
QuantiTect Reverse Transcription kit (Qiagen) k with the RT primers and mix provided by the 
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kit. The reaction was performed at 42° C for 30 min. For all samples, a negative RT was used as 
a control, consisting of an RT reaction omitting the reverse transcriptase. Quantitative RT-PCR 
was performed on cDNA using the Quantitect Probe PCR kitk in a Rotorgene Q PCR cyclerk 
under the following amplification conditions: 95°C for 10 minutes, followed by 40 cycles at 
95°C for 15 seconds and at 60°C for 1 minute. Equal PCR efficiency of all primer pairs was 
validated by serial cDNA dilution. Primers were designed to amplify only equine-specific target 
genes and the housekeeping genes GAPDH, RPL-32 and SDHA: see Table 1 for primer details. 
Flow Cytometry 
Equine iPSC were prepared in PBS, blocked with 0.5% goat seruma, then incubated with mouse 
anti-KRT14 primary antibody (ab 7800m, 1:100) followed by staining with secondary antibody 
R-PhycoErythrin (RPE)-conjugated sheep anti-mouse IgG (115-116-146 h, 1:100 [24]). A 
minimum 20,000 events were analysed by Accuri C6 cytometern and the percent positivity as 
well as mean fluorescence intensity (MFI) for the specific marker calculated based on the 
respective isotype controls. Primary equine keratinocytes served as a positive control and equine 
fibroblasts as negative control. The iPSC were not gated by GFP expression but were sorted 
using the primary antibody followed by the RPE conjugated secondary antibody. 
Scratch wound healing assay 
Equine iPSC-KC and PEK were seeded in 35mm, collagen-coated dishes, at a density of 4 x 105 
cells/cm2. Upon confluence the monolayer cell cultures were treated with mitomycin-Cb 
(50ug/mL) to arrest cell division. The following day, cell cultures were scratched with a sterile 
200uL tip to simulate a wound in vitro [25]. The cells were incubated in a 2% low serum 
medium and migration of eiPSC-KC in comparison to PEK across the scratch wound was 
measured from wounding up to complete coverage of the scratch. The cells were photographed 
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under phase-contrast microscopyi and scratch wound areas were measured using NIH Image J 
softwarej. The mean scratch wound area was calculated from three independent experiments at 
each time point for both cell types. Scratch wound coverage was calculated as a percentage of 
the original wound area, as previously described [26]. 
Population Doubling 
Day 30 differentiated eiPSC (eiPSC-KC) and second passage PEK were seeded in 24-well 
culture dishes at a density of 2 x 104 cells/cm2. Every other day until day 18, cells were 
trypsiniseda then counted using Invitrogen Cell countessa. The cells were expanded for two days 
and trypsinised once confluency was achieved, then replated at the same density. Population 
Doubling value was calculated as log (N/N0) x 3.322, where N = number of cells in the dish at 
the end of a period or growth, N0=number of cells plated in the dish [27]. Data are representative 
of three independent experiments.  
Statistical Analyses 
The temporal variation in keratin markers was analysed using a repeated-measures linear model 
with time as a within-subject factor followed by Tukey’s post-hoc testing to compare the means 
at different time points. For the temporal expression of PANCK, a linear model was used on log-
transformed data with time as a factor controlling for the unequal variances at different time 
points, followed by Tukey’s post-hoc testing to compare the means at different time points. A 
priori contrasts were used to compare treatment means at different time points, and means at 
different time points for each cell type while adjusting alpha level for each comparison using the 
Bonferroni sequential procedure. For log-transformed cell counts, the same model was used 
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except the contrasts were limited to a comparison of the treatment means at each time point. A 
similar analysis was used for log-transformed wound area data. Results are presented as mean ± 
SD of independent technical replicates. Statistical analyses were carried out with SAS v. 9.3o and 
the level of statistical significance was set at P<0.05. 
Results  
Differentiated eiPSC-KC adopt a polyhedral / cobblestone morphology similar to PEK 
Undifferentiated eiPSC form distinctive rounded colonies with well-defined borders and high 
cell density characteristic of iPSC cultures on MEF (Fig. 1A). Moreover, undifferentiated eiPSC 
express pluripotency markers that are lost upon differentiation into eiPSC-KC (Fig. 1B). Upon 
ectodermal differentiation, eiPSC adhere to collagen-coated culture dishes and display initial 
heterogeneous cell populations containing cuboidal epithelial forms and smaller circular cells. 
After two weeks in the keratinocyte differentiation media and further passaging, differentiated 
eiPSC-KC adopt a homogeneous, polygonal or 'cobblestone' epithelial morphology resembling 
that of PEK (Fig. 1A).  
Differentiated eiPSC-KC show increase in pancytokeratin expression  
Equine iPSC began expressing PANCK, a specific marker of epithelium, after 7 days of 
ectodermal specification, with peak expression after 30 days of differentiation (Fig. 2A). A 
gradual, 2.5 fold increase in the first week followed by a 4.8 fold increase at day 30 was 
measured in response to the directed differentiation protocol (P<0.001) (Fig. 2B). Statistically 
significant differences were found between days 0 and 7, between 7 and 15 and 0 and 30 days of 
treatment (P<0.001). At day 30, PANCK expression levels in differentiated eiPSC were not 
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different from those of PEK, indicating their similarity to the keratinocytes originated from adult 
skin epithelia.   
Differentiated eiPSC upregulate the expression of epidermis-specific genes 
In response to ectodermal morphogens, eiPSC showed an increase in expression of KRT18 from 
day 7 of ectodermal specification. Statistically significant upregulation was found at 7, 14 and 30 
days of differentiation (P<0.0001) (Fig. 3A). A statistically significant upregulation of KRT14 
was observed both at days 7 and 14 (P=0.003), with peak expression after 14 days of 
differentiation (Fig. 3B). Further, expression of epidermal stratification markers KRT10 and IVL 
was upregulated in response to the differentiation protocol. Expression of KRT10 increased in a 
statistically significant manner between days 0 and 30 (Fig. 3C). Involucrin, expressed in 
terminally differentiating epidermal cells, was significantly upregulated in eiPSC at 7 ands and 
14 days of directed differentiation (P=0.005) (Fig. 3D).  
Differentiated eiPS-KC express the keratinocyte stem cell marker KRT14  
Keratin 14 is expressed by keratinocyte stem cells, from which the supra basal layers of the 
epidermis develop. To determine the efficiency of the directed differentiation protocol, the 
percentage of the cell population expressing this basal keratinocyte marker was calculated. Flow 
cytometric analysis revealed that 82.5% of eiPSC expressed KRT14 after 30 days of directed 
differentiation (Fig. 4), in comparison to 90.9% of PEK. These data suggest that a high purity of 
epidermal basal stem cell population has been obtained.  
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Equine iPSC-KC migrate to cover the scratch wound and have a greater proliferative capacity 
than PEK 
Equine iPSC-KC are able to heal an in vitro scratch wound by exhibiting forward migration (Fig. 
5A). The wound created in mitomycin-treated monolayers of eiPSC-KC was found to be covered 
at 96h, at which time complete wound coverage was achieved in PEK scratched monolayers. 
Data are presented as mean ± SD (Fig. 5B). The means for percent wound coverage at 72h and 
96h were significantly larger than the means at 0h, 24h and 48h of wound coverage in both 
eiPSC-KC and PEK (P<0.0001). There were no statistically significant differences in percent 
wound coverage between eiPSC-KC and PEK throughout the study.  
Equine iPSC-KC were found to have a greater proliferative capacity compared to PEK (Fig. 5C). 
While PEK enter the stationary phase of cell growth after 8-9 passages when cultured in low 
calcium media, eiPSC-KC continue to proliferate for more than 35 passages (data not shown). 
Statistically significant differences were found between eiPSC-KC and PEK at days 12 (P = 
0.0002), 14 (P < 0.0001), 16 (P = 0.006) and 18 (P = 0.0007) of culture.  
Equine iPSC-KC respond to a high calcium medium similarly to PEK  
Equine iPSC-KC proliferated in low calcium medium similarly to PEK, as evidenced by 
immunoreactivity to Ki67 (Fig. 6). Basal keratinocytes can be induced to terminally differentiate 
when exposed to high levels of extracellular calcium [28]. In this study, both cell types 
underwent growth arrest in response to an elevation in extracellular calcium concentration, as 
evidenced by loss of immunostaining.  
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Discussion  
Differentiation of iPSC into cells of the keratinocyte lineage should contribute to the 
development of customised therapies to regenerate skin lost to injury or disease. In this study, 
ectodermal morphogens RA and BMP-4 used sequentially and at specific concentrations 
successfully induced stepwise progression through appropriate intermediate developmental 
stages prior to generating a differentiated keratinocyte [29; 30]. The combined use of BMP4 (25 
ng/ml) along with RA (1 µM) in specific concentrations has been shown to block the neural fate 
and allow the development of surface ectoderm [18; 31]. The exact role of BMP4 signaling in 
ectodermal development remains unclear however, prior studies have suggested synergism of 
RA and BMP signalling during directed epithelial differentiation of human ESCs [32]. 
Indeed, the directed differentiation protocol caused a 4.8 fold increase in expression of PANCK, 
a protein specific to  epithelium, after 30 days. Moreover, sequential expression of KRT genes 
upon eiPSC differentiation correlated with their expression in keratinised epidermis of the fetal 
vertebrate [33]. During embryonic development KRT18, then KRT14, are expressed by the basal 
cells of the epidermis. Similarly, eiPSC began expressing these ectodermal markers upon 
directed differentiation and, eiPSC-KC finally expressed key markers of epidermal stratification, 
KRT10 and IVL [34].	  Although keratins are also expressed by simple epithelia, epidermal 
keratinocytes can terminally differentiate into stratum corneum and express epidermis specific 
markers KRT 10 and IVL, as shown in this study. Since IVL is absent in simple mucosal epithelia 
and expressed only in keratinised epidermis having the capacity to stratify, our results confirm 
the generation of eiPSC-KC comparable to epidermal cells in vivo.   
Directed differentiation yielded a population of basal eiPSC-KC of high purity similar to that 
obtained in a recent study [35]. Indeed, FACS revealed that 82.5% of the eiPSC population 
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expressed KRT14 specifying the epidermal basal cell subtype. Such a population is ideal for cell 
grafting since it can give rise to the supra basal layers of the epidermis due to its high 
proliferative potential and mitotic capacity [36]. Importantly, no pluripotent cells remained in 
culture after 15 days of directed differentiation, confirming the absence of heterogeneous 
(undifferentiated) iPSC that could, in principle, lead to teratocarcinoma formation [37].  
Epidermal cells can be induced to differentiate and stratify, with concurrent changes in 
morphological characteristics [38], by increasing the calcium concentration of the media [39]. In 
high calcium media eiPSC-KC assumed a flattened cuboidal morphology similar to that of PEK, 
indicating their ability to form corneocytes as seen in vivo [40]. Moreover, while both eiPSC-KC 
and PEK continued to form monolayers in low calcium media, their ability to proliferate was 
compromised by high extracellular calcium. These results suggest that eiPSC-KC are 
functionally similar to PEK.  
In addition to their capacity for self-renewal, a significant advantage of iPSC derivatives over 
PEK is their proliferation potential. In horses, PEK have a low proliferative capacity [41], 
undergo stratification and exit the cell cycle earlier than eiPSC-KC making them inferior to 
populate tissue-engineered constructs. Moreover, the in vitro wound healing assay used in this 
study confirms the migratory ability of eiPSC-KC [42]. Previous studies suggest that immature / 
semi differentiated cells undergo maturation in the microenvironment of the graft [43]. While the 
eiPSC-KC derived in this study show morphology and marker expression characteristic of 
keratinocytes, their true identity and function remain to be determined via functional assays. 
Should in vivo experiments involving transplantation of these eiPSC derivatives into 
experimental equine wound healing models confirm their capacity to survive, engraft and 
integrate into host tissues, these abilities of eiPSC-KC would be of benefit in the regeneration of 
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functional skin lost to injury or disease. Interestingly, studies in other species have shown that 
iPSC-derivatives, both autogenous and allogeneic, are lowly immunogenic [44]. Undifferentiated 
allogeneic eiPSC were similarly found to be weakly antigenic upon intradermal transplantation 
in horses [45], suggesting that allogeneic eiPSC (and their derivatives) might eventually provide 
an 'off-the-shelf' product for wound management.  
An exciting new study reports the isolation and characterisation of bipotent epithelial stem cells 
(EpSC) from equine skin, showing differentiation into keratinocytes and adipocytes [46]. The 
advantage of developing an eiPSC-KC based construct is that the latter cells have the capacity to 
regenerate not only the different layers of the epidermis but also accessory adnexal structures of 
the skin, as shown convincingly in a mouse model [18].  
Conclusions  
This preclinical, “proof of concept” study reports an efficient method to differentiate equine 
iPSC into a keratinocyte lineage. Moreover, we describe the morphological and functional 
characterisation of the differentiated eiPSC-KC, including the migratory ability to cover wounds. 
The resulting cells, eiPSC-KC, show features that are promising to the development of a stem 
cell-based skin construct with the potential to fully regenerate lost or damaged skin.  
Manufacturers’ details: 
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fCorning Incorporated, Corning, NY, USA 
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Figure Legends: 
Fig. 1: (A) Confocal microscopic image of a characteristic eiPSC colony with defined borders 
and high cell density (left). Images were photographed with an Olympus FV1000 laser-scanning 
microscope. Scale bar 100µm. Equine iPSC-KC (centre) showing typical 'cobblestone' 
morphology similar to PEK cultures (right). Centre and right images were photographed with an 
Axio Observer Z1 microscope. Scale bar 50µm. 
(B) Equine iPSC show the endogenous expression of key pluripotency genes NANOG, SOX-2, 
OCT-4 and KLF-4 that is lost upon differentiation into keratinocytes (eiPSC-KC). 
(C) Schematic representation of the protocol used for differentiation of eiPSC into epidermal 
cells (eiPSC-KC). 
Fig. 2: (A) Sequential increase in expression of PANCK in eiPSC after 7, 14 and 30 days of 
directed differentiation, as detected by immunofluorescence, in comparison to undifferentiated 
eiPSC (at day 0) and PEK. Columns from left to right show counterstaining with DAPI (staining 
nuclei blue), PANCK positive cells (staining red), and DAPI+PANCK merge. Scale bar 100µm.  
(B) Mean fluorescence intensities (MFI), calculated by Image J, in PANCK+ cells after 7, 14 and 
30 days of directed differentiation in comparison to eiPSC before induction and PEK as positive 
control (n=3). Horizontal bars with asterisks represent group differences (*P<0.0001). There was 
no statistically significant difference between day 30 eiPSC-KC and PEK however, there were 
differences between days 0, 7 and 15. Data expressed as mean ± SD. 
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Fig. 3: Temporal gene expression by eiPSC in response to treatment with ectodermal 
morphogens. (A) KRT18 (B) KRT14 (C) KRT10 (D) IVL. Values are normalised to the mean 
expression values of the housekeeping genes GAPDH, RPL-32 and SDHA. Means that share the 
same letters are not statistically significantly different. Data expressed as mean ± SD. 
Fig. 4: Flow cytometric analysis of eiPSC-KC showing keratin 14+ cells in response to the 
directed differentiation protocol, in comparison to control PEK and undifferentiated eiPSC. Red 
line indicates KRT14 staining and black line indicates isotype control.   
Fig. 5: (A) In vitro scratch wound healing assay showing migration of eiPSC-KC in comparison 
to control PEK that cover the scratch wound at 96h. Black dotted lines indicate the scratch 
wound margins. 
 (B) Graph showing scratch wound coverage by migration of eiPSC-KC and PEK. Images were 
photographed with an Axio Observer Z1	  and percent coverage was calculated using Image J 
software. Data are presented as mean ± SD of three independent experiments.  
(C) Population doubling of eiPSC-KC after formation of epidermal cells in comparison to 
control PEK cultures. Data are presented as mean ± SD of three independent experiments.   
Fig. 6: Equine iPSC-KC and PEK cultured in low calcium medium show cell proliferation by 
positive immunoreactivity for Ki67. Cell cycle arrest occurs in response to high calcium 
concentration, as evidenced by loss of immunostaining. (Scale bar 50µm).   
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Table 1: Primer sequences of analysed genes. 
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(A) Confocal microscopic image of a characteristic eiPSC colony with defined borders and high cell density 
(left). Images were photographed with an Olympus FV1000 laser#scanning microscope. Scale bar 100µm. 
Equine iPSC#KC (centre) showing typical 'cobblestone' morphology similar to PEK cultures (right). Images 
were photographed with an Axio Observer Z1 microscope. Scale bar 50µm.  
(B) Equine iPSC show the endogenous expression of key pluripotency genes NANOG, SOX#2, OCT#4 and 
KLF#4 that is lost upon differentiation into keratinocytes (eiPSC#KC).  
(C) Schematic representation of the protocol used for differentiation of eiPSC into epidermal cells (eiPSC#
KC).  
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(A) Sequential increase in expression of PANCK in eiPSC after 7, 14 and 30 days of directed differentiation, 
as detected by immunofluorescence, in comparison to undifferentiated eiPSC (at day 0) and PEK. Columns 
from left to right show counterstaining with DAPI (staining nuclei blue), PANCK positive cells (staining red), 
and DAPI+PANCK merge. Scale bar 100µm.  
(B) Mean fluorescence intensities (MFI), calculated by Image J, in PANCK+ cells after 7, 14 and 30 days of 
directed differentiation in comparison to eiPSC before induction and PEK as positive control (n=3). Horizontal 
bars with asterisks represent group differences (*P<0.0001). There was no statistically significant difference 
between day 30 eiPSC8KC and PEK however, there were differences between days 0, 7 and 15. Data 
expressed as mean ± SD.  
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Equine iPSCKC and PEK cultured in low calcium medium show cell proliferation by positive immunoreactivity 
for Ki67. Cell cycle arrest occurs in response to high calcium concentration, as evidenced by loss of 
immunostaining. (Scale bar 50µm). 
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V. General Discussion 
A. Undifferentiated eiPSC weakly express molecules of the MHC  
The high polymorphism of the MHC complex represents a considerable barrier in 
tissue transplantation since incompatibility between donor and recipient may lead to 
immune rejection. Data showed that reprogrammed parental fibroblasts significantly 
downregulate MHC expression. One of the eiPSC lines analyzed for MHC expression 
(MHC-I = 4% and MHC-II = 1%) was injected into the horse from which it was derived, 
thereby serving as an autologous eiPSC control. While this line did not elicit acute graft 
rejection, it did cause the formation of inflammatory foci within the dermis, similarly to the 
allogeneic eiPSC line (MHC-I = 1% and MHC-II = 12%), presumably due to cell line 
differentiation or transient culture conditions that upregulate MHC-II expression [179]. 
Analysis of an eESC line that served as an in vitro cell control showed that MHC-I 
expression was low (2.5%), however MHC-II expression was far greater (27%) than 
observed in other species [180] (data in appendix- Fig. A1). Equine eESC are rather an ES-
like trophoblast cell line contaminated by other cell types [80]. Moreover, they have been 
shown to differentiate very rapidly and spontaneously into various cell types (a significant 
drawback with most veterinary ESC lines). Nevertheless, no other in vitro studies have 
measured MHC expression in eESC and there may be differences among cell lines. 
Because they are allogeneic (and embryonic) in origin, eESC might have been an 
appropriate (positive) cell control with which to compare the immunogenicity of eiPSC in 
vivo. However, due to the difficulty in keeping them in an undifferentiated state [103] and  
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their high MHC-II expression, that could further be upregulated upon differentiation in 
vivo, eES-like cells may not be suitable for clinical applications.  
Since the aim of my first study was to determine the immunogenicity of allogeneic 
eiPSC, ELA typing was carried out to confirm the allogeneic nature of the eiPSC line to be 
transplanted intradermally. Genomic DNA from skin samples obtained from the 
experimental horses was used for microsatellite PCR amplification and fragment analysis, 
carried out by Dr. Antczak at the Baker Institute for Animal Health (Cornell University) – 
see supplementary data of article 1. 
An advantage of the eiPSC used in my studies is their expression of GFP, a reporter 
gene enabling the identification of iPSC colonies successfully transfected with the 
exogenous pluripotency factors. An incidental finding was that eiPSC were heterogeneous 
with respect to GFP expression and cell size, as observed in other species [181]. In any 
case, pluripotency is unrelated to cell size and to GFP expression. Further, GFP is an 
unstable protein and spontaneous silencing of transgenes can occur in ESC and iPSC, a 
common manifestation in transgenic animals [182]. Nevertheless, the GFP protein may 
trigger an inflammatory response in the host, potentially contributing to graft rejection 
[183]. Thus, stem cell differentiated derivatives should ideally not be marked with GFP in a 
clinical setting.  
B. Undifferentiated eiPSC elicit a chronic inflammatory response in   
immunocompetent hosts 
In vitro studies have mostly shown that autologous, undifferentiated murine and 
human iPSC are lowly or non immunogenic [158], though a study by Zhao et al. (2011) 
found that autologous, undifferentiated iPSC elicit an immune response in syngeneic mice 
102	  
[136]. Interestingly, my histologic data reveal no statistically significant difference in the 
inflammatory response elicited by autologous or allogeneic undifferentiated eiPSC (data in 
appendix- Fig. A2). Both autologous and allogeneic eiPSC-injected sites initially formed 
small inflammatory foci that grew larger over 30 days, with inflammatory exudate 
extending throughout the dermis. A recent study in mice demonstrated that 
undifferentiated, allogeneic iPSC survive and proliferate in immunocompetent recipients 
early post-transplantation, accompanied by a mild immune cell infiltration [184]. My study 
extends these findings to a large animal model. The GFP+ eiPSC were detectable up to one 
week post-transplantation in tissue sections of injected sites. Infiltration of CD4+ and CD8+ 
T-cells around the transplantation sites suggests activation of the immune system. These 
data imply the development of a chronic and progressive inflammatory response to eiPSC 
in the MHC-mismatched hosts, with persistence of CD4+ and CD8+ T-cells that 
increasingly infiltrated the transplanted site over 30 days, in comparison to saline-injected 
controls. The absence of GFP+ eiPSC at the site of transplantation after seven days may be 
due to migration of the cells away from the site or phagocytosis and lysis of the cells by T-
cell mediated effects. The undifferentiated eiPSC, being doxycycline dependent, require 
other cytokines such as LIF, bFGF etc. to sustain their undifferentiated state, possibly even 
in in vivo conditions [87]. The absence of these stimuli in the dermis may have caused 
sluggish activity or death of the transplanted eiPSC.  
The eiPSC used in my study require the continuous expression of doxycycline 
controlled reprogramming factors to maintain pluripotency [87]. Because previous studies 
show an association between the reprogramming factor c-MYC and the formation of 
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malignant neoplasms [185], the eiPSC were cultured in doxycycline-free media prior to 
transplantation, in order to eliminate potential tumorigenicity associated with c-MYC. In 
doing so, loss of reprogramming transgenes occurred after 48h (data in appendix- Fig. A3). 
Predictably, there was a concurrent significant downregulation of pluripotency genes 
NANOG, c-MYC and KLF-4, suggesting the initiation of differentiation of eiPSC (data in 
appendix- Fig. A4). Nevertheless, the eiPSC continued to express pluripotency genes 
(albeit at a lower level), compared to eiPSC cultured in doxycycline containing media (data 
in appendix- Fig. A5). Further, there was no remarkable change in MHC-I or II expression 
by eiPSC after 48h in doxycycline-free media (data in appendix- Fig. A6). These 
preliminary data are promising since culturing in doxycycline-free media reduces potential 
tumorigenic risk of the transgenes, especially c-MYC, while early differentiation of eiPSC 
does not seem to increase their immunogenic potential. The absence of teratocarcinomas in 
this study is possibly attributed to factors such as the site of transplantation, the use of 
immunocompetent animals and the type of non-genomic integrating eiPSC.  
Because iPSC are unlikely to spontaneously differentiate into a desired cell lineage 
in vivo, due to the absence of external morphogens or stimulants to direct their 
differentiation [128], the next step of my project aimed to develop an efficient method to 
drive the differentiation of eiPSC into a keratinocyte lineage, of interest for coverage of 
wounds in horses. 
C. Standardized protocol to drive eiPSC to commit to a keratinocyte lineage 
In this study, a specific combination of signalling molecules induced iPSC 
differentiation by recapitulating the conditions occurring during embryogenesis [186]. 
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Thus, sequential application of ectodermal morphogens RA and BMP-4, directs the 
differentiation of iPSC towards ectoderm and finally keratinocytes of the epidermis. 
Various concentration (0.5, 1, 1.5, 2µM) of RA and BMP-4 (25ng/ml) were applied to 
eiPSC, either together or sequentially (data not shown), and it was found that 
concentrations of 1µM RA for three days, followed by 25ng/ml of BMP-4 for three days 
were most effective for inducing ectodermal differentiation in the equine iPSC model, 
reflecting previous studies carried out in man and mice [124; 128]. Controls for this 
directed differentiation protocol were undifferentiated eiPSC cultures, separated from 
feeder layers but not treated with ectodermal morphogens.  
In response to precise induction with ectodermal morphogens, undifferentiated 
eiPSC were driven to eiPSC-KC that express keratinocyte markers at both gene and protein 
levels. The eiPSC-KC expressed KRT18, KRT14, KRT10 and IVL as shown in prior iPSC 
differentiation studies [128; 131]. The antibody clone used to measure PANCK expression 
in response to the differentiation protocol is a cocktail of high molecular weight (MW) 
KRT 1, 2, 3, 4, 5, 6, 10, 14, 15 and 16, and low MW KRT 7, 8 and 19 (verified by WB, 
data in appendix- Fig. A7). Thus, immunostaining with this antibody implies expression of 
several of these keratins specific to the epidermis suggesting successful differentiation. 
Expression of genes of suprabasal layers of the epidermis (KRT 10, IVL) indicates 
keratinization, a characteristic absent in other stratified squamous epithelia such as 
esophagus, oral mucosa, cornea etc. 
In addition, flow cytometry confirmed that a highly pure population of cells of the 
basal epidermal subtype were obtained following the differentiation protocol: 82.5% of the 
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differentiated eiPSC expressed KRT14, in comparison to 90.9% of the PEK (positive 
control). However, the concentration of molecules on the surface of eiPSC-KC varied from 
that on PEK, evidenced by differences in fluorescence intensities measured by cytometry. 
However, the concentration of molecules on the surface of eiPSC-KC varied from that on 
PEK, evidenced by differences in fluorescence intensities measured by cytometry 
suggesting differences in distribution of surface molecules between eiPSC-KC and their 
primary counterparts. Nevertheless, the purity achieved in my study is comparable to that 
of a recent study in man (75% KRT 14+ cells and 86% KRT 14+ cells) using the same 
ectodermal inducers [128; 131].  
Normal mouse and human keratinocytes proliferate when cultured in low calcium 
media and can be induced to terminally differentiate and stratify when exposed to higher 
levels [36]. This was shown by prior studies that investigated the effects of a 'calcium 
switch', beginning with low calcium media (0.02mM) and increasing through gradients of 
0.5, 1, 2, 4, 6 and 8mM [187]. Both eiPSC-KC and PEK suffered cellular detachment and 
apoptosis when culture in media with concentrations >5mM calcium. The two cell types 
(eiPSC-KC and PEK) were therefore treated with 1.8mM calcium (based on the results of a 
titration assay) for up to three days. Analysis of keratin genes and IVL did not show 
discernible changes in response to calcium for either cell type (in response to calcium 
treatment, basal keratinocytes markers KRT 5 and KRT 14 are expected to decrease, with an 
increase in suprabasal markers IVL and KRT 10). Nevertheless, the calcium switch did 
induce morphological changes and growth arrest in both eiPSC-KC and PEK suggesting 
calcium had artificially induced terminal differentiation as seen by the squames floating in 
106	  
the culture media. These results are in accordance with those observed in previous 
differentiation studies [186]. 
D.  Primary equine keratinocytes (PEK) cell culture 
Primary equine keratinocytes isolated from horse skin have not been widely 
characterized, although there have been reports of PEK isolated from equine hoof and lip 
epithelium [188; 189]. Recently, PEK monolayers were obtained from skin explants in 
horses [60] however this approach may be plagued by variations in cellular composition 
leading to susceptibility to fibroblast overgrowth, poor subculturability and low growth rate 
[190]. I developed a modified culture system with low serum medium of 2% based on 
techniques used for keratinocyte isolation in mice and man, and a single report in horses 
using 10% serum containing keratinocyte medium [189]. The PEK obtained by this method 
were negative for vimentin, a marker of fibroblasts, confirming that fibroblast-free cultures 
of PEK were obtained (data in appendix- Fig. A8) contrary to what is usually achievable 
using explant cultures [190].  
The recent development of equine skin equivalents (ESE), seeded with PEK and 
dermal fibroblasts, with the ability to form suprabasal skin layers in 3D models is exciting 
[60] [191]. However, a major caveat of these latest studies is the absence of a 
comprehensive molecular characterization necessary to confirm their identity as PEK, and 
absence of data on proliferative and migratory capacities. Another recent addition to equine 
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regenerative medicine is the isolation, from equine skin, of EpSC [192] capable of self-
renewal and with a bipotent differentiation capacity (into keratinocytes and adipocytes). 
These cells displayed regenerative capabilities by increasing vascularization, elastin content 
and follicle-like structures when implanted into experimental skin wounds in horses. 
Equine iPSC-KC should be tested in this in vivo wound model to the respective abilities of 
these two cells types to engraft and regenerate skin and its appendages.  
E. Phenotype and function of eiPSC-KC and PEK 
The eiPSC subjected to the directed differentiation protocol described herein rapidly 
undergo morphologic changes, assuming epithelial cell morphology; the cells take on a 
typical cobblestone appearance, characteristic of keratinocytes of the epidermis [193] and 
undergo terminal differentiation in response to the calcium switch (low to high). These 
keratin-expressing cells attach to collagen-coated dishes, a characteristic of KSC, which 
concurs with the behavior of mouse and human iPSC transformed into a multipotent 
keratinocyte lineage [128]. Based on these attributes, differentiated eiPSC were found to 
have a similar phenotype to PEK.  
To further demonstrate that differentiated eiPSC are functionally similar to PEK and 
therefore warrant the appellation 'eiPSC-KC', a wound healing assay was performed to 
predict their ability to heal an in vitro wound created in a monolayer of cells. To my 
knowledge, no previous study reports the use of such an in vitro wound healing assay for 
PEK, however my data parallel those of mouse and human models [194]. Results suggest 
that eiPSC-KC and PEK would be equally valuable for application on in vivo wound 
healing models. Importantly, eiPSC-KC showed greater proliferative capacity compared to 
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PEK that had a limited life span. Thus, eiPSC-KC may be superior alternatives in clinical 
settings since they could be used to generate a large number of cells required to populate 
the graft in vivo. Equine iPSC-KC consist of KRT14 basal epidermal cells that have the 
capacity to form the suprabasal layers of the epidermis. An advantage of my study design is 
the feeder free system used to generate eiPSC-KC, making these cells ideal for future 
transplantation in horses since free of xenogeneic components that would necessarily 
increase immunogenicity. It is expected that eiPSC-KC would have the capacity to 
differentiate into the adnexal structures of the epidermis, as shown in previous in vivo 
mouse models [128], essentially regenerating the skin by restoring pigmentation, nerve and 
vascular plexuses as well as immune capabilities.  
VI. Study Limitations
A. Immune response to undifferentiated eiPSC 
Prior to transplanting cells into the experimental subjects, the MHC expression of 
undifferentiated eiPSC was measured in an effort to predict the eventual in vivo immune 
response. While MHC expression by the two available eiPSC lines was low, analysis of 
additional lines would enable selection of the least immunogenic lines. Although the in vivo 
portion of my study has provided valuable information on the horse’s immune response to 
transplantation of eiPSC, the data must be interpreted with caution since limited to two 
horses. Moreover, while the dose of eiPSC (1x106) was based on that currently used in 
mouse models [136], due to technical difficulties and time constraints it was unfortunately 
impossible to generate sufficient numbers of cells to inject all the sites in both horses, such 
that a single allogeneic line provided duplicate data sets.   
Skin samples were obtained at days 2, 3, 7 and 30 following intradermal 
transplantation of eiPSC. While these times were based on a previous study model, chronic 
inflammation may have persisted and evolved beyond the study duration, causing tissue 
fibrosis and scarring [195] which, in this study, went unobserved. A considerable technical 
difficulty with flow cytometry was that the overlap of GFP expression by eiPSC and 
secondary antibody staining (R-Phycoerythrin) hindered fluorescence compensation of 
GFP. This might be overcome by using a GFP- eiPSC line; as this was unavailable we used 
the parental fibroblast cell line as a negative control to enable determination of 
immunolabelling with the secondary antibody. This situation could be avoided in the future 
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by staining with fluorochromes further ahead in the fluorescent spectrum such as APC or 
Alexafluors (Alexa647) with wavelengths >650nm.   
Because the eiPSC used in this study were doxycycline dependent, the withdrawal 
from doxycycline may have lead to the death of these cells in vivo. While supplementation 
of doxycycline in the feed might have sustained the survival of eiPSC in vivo, this is not 
easily feasible in horses due to cost and toxicity concerns. No doubt the most significant 
limitation of the first study is that undifferentiated eiPSC were studied, which does not 
reflect the scenario likely to be used clinically. Therefore, this experiment should be 
repeated using differentiated derivatives of potential clinical utility, such as the eiPSC-KC 
subsequently developed.   
B. Differentiation of eiPSC into keratinocytes 
The next objective of my PhD research was to differentiate eiPSC to a keratinocyte 
lineage given the therapeutic potential of this cell type in wound management. A major 
caveat of this second study is that the protocol I developed was fully successful in a single 
eiPSC line. While reproducible in the same eiPSC line, other available eiPSC lines did not 
respond similarly, even with varying concentrations of the ectodermal morphogens RA and 
BMP-4, possibly due to dissimilar differentiation capacities [196].  
Another drawback was that the available eES-like lines and undifferentiated eiPSC 
lines had inherent keratin expression suggesting epigenetic memory or incompletely 
reprogrammed keratinocytes in these lines as also observed in human iPSC lines [197]. The 
H2A line used in this study showed baseline expression of KRT14 prior to being subjected 
to the directed differentiation protocol, which was not the case in other species’ iPSC 
subjected to the same protocol [131]. This baseline expression was also seen in WB by  
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PANCK staining of undifferentiated eiPSC lysates (data in appendix- Fig. A7). 
Differentiated eiPSC-KC expressed high MW keratins (similar to PEK) as well as low MW 
keratins, confirming the expected keratin upregulation in response to the differentiation 
protocol. While undifferentiated eiPSC also expressed (baseline) high MW keratins, this 
may be attributed to contaminating MEF in addition to inherent keratin expression by the 
H2A line. This baseline keratin expression of the H2A line is attributable to either 
epigenetic memory or contamination with keratinocytes that were unsuccessfully or 
incompletely reprogrammed since fetal tissue (skin with underlying cutaneous muscle) was 
used for reprogramming [197]. Moreover, studies have documented that iPSC show 
preferential lineage-specific differentiation such that the phenotype may be influenced by 
the cell of origin [198], a characteristic that might well be exploited therapeutically [199].  
Next, the absence of commercial, equine-specific antibodies against protein markers 
of the KSC limited my ability to fully compare the obtained eiPSC-KC population to the 
'true' keratinocytes (PEK). In this regard, it has been reported that only 4% of human 
antibodies react with the equivalent equine epitopes [200]. Finding suitable antibodies is, 
therefore, a challenge in equine studies.  
An important clinical consideration is the time required to generate autologous 
iPSC-KC grafts for wound management. Reprogramming of iPSC from patient fibroblasts 
is followed by characterization of the iPSC line, done by karyotyping, flow cytometry 
analysis of pluripotency genes, qRT-PCR analysis, differentiation analysis in vitro and in 
vivo for each germ layer. All of these assays require >5 weeks to derive an established 
autologous iPSC line. Subsequently, the protocol to differentiate iPSC into keratinocytes 
requires an additional 4-5 weeks of waiting time. Thus, allogeneic iPSC-KC might be 
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superior for clinical use since they could be prepared in advance and banked. Alternatively, 
autologous PEK-derived grafts, engineered in approximately three weeks, may be suitable 
temporary dressings to be used while awaiting the preparation of autologous eiPSC-KC 
grafts, should further studies reveal that immunogenicity of allogeneic products is 
excessive. 
VII. Research Perspectives
 A. Immunogenicity of eiPSC 
A consensus as to the effect of the reprogramming method on the immunogenicity 
of iPSC has yet to be reached. Consequently, reports on the immunogenicity of iPSC 
derivatives are contradictory, although the most recent suggests acceptance of skin grafts 
engineered from chimeric iPSC [118]. Thus, studies comparing immunogenicity of non-
virally reprogrammed iPSC and other integration-free lines must be conducted on animal 
models in an effort to determine iPSC lines that are clinically viable. Nevertheless, since 
undifferentiated iPSC are not likely to be useful clinically, most of the following 
suggestions apply to iPSC derivatives, in particular the eiPSC-KC described in the second 
article of this thesis.  
In addition to striving for a better MHC match between host and recipient prior to 
grafting, the immune response might be predicted by performing in vitro Mixed 
Lymphocyte Reaction (MLR) testing [157]. This test aims to estimate histocompatibility 
between the donor and the host. In addition to the MHC antigens, costimulatory molecules 
such as CD40, CD80, CD86 and mHC also play integral roles in activation of the immune 
system by presenting foreign antigens to the TCR. Therefore, to further characterize the 
immunogenicity of eiPSC and better predict the in vivo response to grafting, a 
comprehensive study of surface molecules involved in the immune response must be 
conducted. Of course, analysis of a large number of eiPSC lines is necessary to select, for 
eventual banking purposes, those that are lowly immunogenic on account of their MHC and 
costimulatory molecule expression profile. Analysis of costimulatory molecules on iPSC  
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would additionally permit identification of the activated cells and their pathways, thus 
permitting their blockade, thereby facilitating graft acceptance [201].  
The logical next step would be to determine the ability of iPSC to survive amidst in 
vivo inflammatory conditions, given that the cells are ultimately to be used therapeutically 
for disease conditions involving inflammation. This might be done by challenging eiPSC 
with IFN-ϒ in vitro, in such a manner as to simulate inflammatory in vivo conditions. 
Interestingly, a previous study has shown that undifferentiated iPSC exert paracrine effects 
by homing to the site of acute lung injury in mice and causing downregulation of the 
inflammatory response [202]. Analysis of the MHC molecules in response to simulated 
inflammatory environments (e.g. wounds) will determine the ability of these cells to 
survive amidst the inflammatory mediators and potentially modulate the host environment.  
Because the fate of the transplanted eiPSC is uncertain in my study (no detection of 
the GFP marker beyond seven days of grafting), strategies to improve both in vivo cell 
tracking and graft survival must be developed. Several fluorophores and probes can be 
introduced into stem cells for in vitro and in vivo dynamic tracking, with bioluminescent 
imaging (BLI) modalities such as magnetic resonance imaging and optical or nuclear 
imaging being some of the most common [67]. Moreover, alternative fluorophores, less 
immunogenic than GFP, should be considered for in vivo tracking studies.  
 Detachment of cells in culture from ECM/feeders/attachment to other cells initiates 
the apoptotic pathway (called anoikis) eventually leads to cell death due to the loss of 
adhesion-related survival signals. The concurrent use of biomaterials mimicking the ECM 
has been explored as a means to provide a niche environment rich in pro-survival factors in 
order to increase retention of cells at the site of transplantation [203]. Alternatively, co-
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transplantation of iPSC with other cell types such as MSC or with PRP are interesting 
measures since the latter may ensure immunomodulation and cytokine release at the site of 
transplantation, thereby enhancing graft 'take'.  
B. Differentiation of eiPSC into keratinocytes 
The second article in my thesis describes the generation of eiPSC-KC that are 
phenotypically similar to their primary counterparts (PEK). While the eiPSC-KC do 
express key keratinocyte genes and proteins, differences in the levels of gene transcripts are 
apparent. For example, KRT18 was highly expressed in eiPSC-KC suggesting these cells 
have yet to reach a state of complete differentiation [204]. Further studies are therefore 
warranted to establish the exact differentiation status of these cells. Analysis of other 
markers of basal keratinocytes (e.g α6β4 integrins, α2β1 and α3β1 integrins of the lateral 
surfaces of epidermal basal cells) is warranted. Enrichment of these cells by double 
labelling with antibodies against integrins and key markers such as KRT5, KRT6, KRT15 
and KRT14, is required. Precise in vivo localization of these putative stem cells, to 
determine the niche from which they originate, must be explored to tap into these sources 
for future clinical use. 
In order to confirm the clinical value of the eiPSC-KC generated via the directed 
differentiation protocol I have developed, the ability of these cells to fully integrate and 
develop into the various strata that comprise equine skin must be studied, first in vitro then 
in vivo. Seeding of eiPSC-KC in 3D constructs should help demonstrate this capacity by 1- 
characterizing the construct, using specific markers to determine whether iPSC-KC have 
differentiated into adnexa and 2- raising the 3D construct to the air-liquid interface to verify 
the ability of eiPSC-KC to stratify and form corneocytes. Then, using an in vivo 
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experimental model such as that recently described by Broeckx et al. (2014) [192], the 
contribution of these eiPSC-KC to wound healing in horses could be measured and possibly 
compared to that of equine EpSC.  
While eiPSC-KC have shown promising indications (proliferation potential) of 
being superior to PEK for grafting onto wounds to enhance healing, several questions as to 
their applicability and safety must be answered before they can be considered clinically. In 
the interim, PEK-based grafts might present an interesting but unexplored option for equine 
regenerative medicine. However, KSC specific markers must first be developed to permit 
immunophenotypical characterization of PEK. Efforts to further define basal cells as well 
as determine the source and niche of these cells (e.g.: interfollicular epidermis, hair follicle 
bulge) are required. Enrichment of these respective populations must then be tested in in 
vivo models to confirm the multipotency of these cells. Moreover, improvement of culture 
conditions of PEK is required to prolong their lifespan in vitro; inspiration might come 
from studies in mice and man wherein primary keratinocytes are maintained for >20 
passages [205]. Alternatively, strategies to immortalize PEK lines and/or the development 
of transformed cell lines might produce an important tool for research, similar to the classic 
HaCaT line that serves to study wound repair, cancer, and as platform for gene delivery, 
drug testing [206]. 
VIII. Conclusion
The overall objective of my research program was to develop a tissue engineering 
approach, using stem cells, to improve the management of chronic, non-healing wounds in 
horses. In order to achieve this I first investigated the immune potential of eiPSC in an 
effort to characterize this possible barrier to therapeutic use of eiPSC. Initial enthusiasm for 
PSC derivatives was based on the assumption that they may escape immune surveillance on 
account of low MHC expression. I used an intradermal transplantation model along with 
GFP-marked eiPSC to effectively study, in vivo, the immune response to iPSC in horses. 
My results show that the weak expression of MHC molecules is insufficient to ensure 
engraftment of autologous and allogeneic eiPSC; thus a plethora of other factors must also 
contribute to the immunogenicity of iPSC and thus the success of engraftment of iPSC-
derived grafts. Ultimately, screening and banking of hypoimmune allogeneic eiPSC lines 
should allow selection of those most suited for directed differentiation into lineages of 
clinical interest.  
In equine wound healing, the keratinocyte is of critical importance to ensure proper 
epithelialization and control the development of EGT; unfortunately, this cell population is 
often deficient, particular in the limb wounds of horses. This was the impetus for the 
standardization of a protocol to induce the differentiation of eiPSC into cells of a 
keratinocyte lineage that might ultimately be used to provide effective coverage in the form 
of a graft. Results of my study show that eiPSC-KC express markers characteristic of the 
basal cells of the epidermis and are phenotypically as well as functionally similar to 
primary keratinocytes. Moreover, the demonstrable migratory ability of eiPSC-KC along 
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with their superior proliferative capacity, suggest their value as a cell source for grafting 
onto in vivo models requiring large numbers of highly proliferative cells.  
Taken together, my studies mark a step forward for equine regenerative medicine. 
Nevertheless, before clinical application may be envisaged, several barriers are to be 
overcome. High quality cell products must be developed in good manufacturing practice 
conditions and standardized non-genomic integration derivation methods must be 
developed. Further studies are necessary to ensure consistency and genomic stability of 
PSC derivatives since heterogeneity and tumorigenicity are justifiable concerns. Flow-
based methods to enrich for pure, differentiated populations must be perfected prior to 
clinical use. Finally, the ability of stem cell derivatives to engraft and function in the host 
over the long term is prerequisite to their therapeutic success. The constant evolution of 
regenerative medicine with safe and effective means of using iPSC should help to make 
iPSC-derived grafts the new 'gold standard' for future therapeutics.
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X.  Appendix: Supplementary Results 
Fig. A1: Flow cytometric analysis of MHC expression by equine ES-like cells: Flow 
cytometric analysis of equine ES-like cells shows low MHC-I expression (1%) and high 
MHC-II expression (27%). 
 Fig. A2: H&E section of skin injected with undifferentiated autologous eiPSC 
intradermally in the lateral neck of experimental horses showing moderate immune 
response at days 7(b) and 30(c), and no response at 2 days (a). (Black dotted circles show 
the area of inflammatory response)   
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Fig. A3: Loss of murine transgenes after 48h in doxycycline free media: PCR products 
of line 1 eiPSC confirm presence of the mouse plasmid, that disappears after doxycycline 
withdrawal. Similarly, line 2 eiPSC lose expression of the mouse plasmid in the absence of 
doxycycline. 
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Fig. A4: Reduction in pluripotency genes in the absence of inhibitors: Expression of 
pluripotency genes of eiPSC cultured in complete doxycycline medium (blue bars) and 
gene expression after doxycycline withdrawal for 48h (red bars) shows reduction in levels 
of NANOG, OCT 3/4, KLF-4 suggesting initiation of differentiation in eiPSC lines 1 and 2.  
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Fig. A5: Persistent pluripotency gene expression after 48h: PCR products of eiPSC lines 
1 and 2 after doxycycline withdrawal for 48h show expression of pluripotency genes 
NANOG, SOX-2, OCT-4 and KLF-4.  
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Fig. A6: Flow cytometric analysis of MHC expression by undifferentiated eiPSC: 
MHC expression by lines 1 and 2 in complete iPSC media and in inhibitor free media 
(doxycycline and LIF free media) for 48h. Equine iPSC line 1 had MHC-I expression of 
2.8% and MHC-II expression of 2.5% in eiPSC media. After 48h of inhibitor withdrawal, 
MHC-I expression was of 4.2% and MHC-II expression was of 3.4%. Similarly, eiPSC line 
2 showed MHC-I expression of 3.3% and MHC-II expression of 7.8%. After 48h of 
inhibitor withdrawal, MHC-I expression was of 0.2% and MHC-II expression was of 0.7%. 
These data suggest that doxycycline removal does not increase immunogenicity by MHC 
expression. 
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Fig. A7: Immunoblot of Pancytokeratin: PANCK has MW ranging from 40-67kDa. PEK 
show higher MW keratins (50-60 kDa), whereas eiPSC-KC show low MW keratins (40-60 
kDa). Undifferentiated eiPSC also express low and high MW keratins (40-60 kDa). 
 
 
Fig. A8: Immunoblot of Vimentin: Cell lysates of fibroblasts have a molecular weight 
(MW) of 60 kDa whereas PEK are negative for Vimentin.  
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Fig. A9: Flow cytometric analysis of MHC expression by PEK and eiPSC-KC: MHC-I 
expression of PEK was 99.5% and that of eiPSC-KC was 20.18%.  MHC-II was of PEK 
was 27% and that of eiPSC-KC was14.7%.   
	  
	  
	  

